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Here, then are the true characteristics of objectivity…Objectivity does not 
demand that we estimate man’s significance in the universe by the minute 
size of his body, by the brevity of his past history or his probable future 
career.  It does not require that we see ourselves as a mere grain of sand 
in a million Saharas.  It inspires us, on the contrary, with the hope of 
overcoming the appalling disabilities of our bodily existence, even to the 
point of conceiving a rational idea of the universe which can 
authoritatively speak for itself.  It is not a counsel of self-effacement, but 
the very reverse—a call to the Pygmalion in the mind of man. 
 
- Michael Polanyi, 1958, Personal Knowledge   
 
 
 
 
 
 
 
 
 
 
iv 
 
Acknowledgements 
 
 I am truly in debt to a number of people with whom I have interacted and worked 
with during my stay here at Caltech.  First, I would like to thank my advisor Professor 
Jim Heath.  Of the many things that I have learned from him, I hold in high regard his 
intensity and infectious passion for science.  I would like to thank him for the academic 
freedom he grants his students, and for the incredible resources he makes available for his 
group, including the organization of the Nanosystems Biology Cancer Center (NSBCC) 
between Caltech, UCLA and the Institute for Systems Biology (ISB).  I would like to 
offer my gratitude to many senior collaborators within the NSBCC, including Professor 
Caius Radu (UCLA), Professor Antoni Ribas (UCLA), Professor Paul Mischel (UCLA), 
Dr. Leroy Hood (ISB), Professor Mike Phelps (UCLA) and Professor Owen Witte 
(UCLA) all of whom have helped during my graduate career either in providing access to 
the resources in their labs or project guidance.  I would like to thank Professor Ton 
Schumacher (NKI) for many insightful email exchanges regarding the NACS project.  I 
would like to thank Professor Pamela Bjorkman, Professor Sarkis Mazmanian and 
Professor Chin-Lin Guo for agreeing to serve on my thesis committee with little prior 
notice.   
 I had the pleasure of interacting with many intelligent and talented co-workers 
within the Heath group.  I would like to thank Dr. Ryan Bailey with whom I co-
developed the DEAL platform with.  I wish him the best in his lab at UIUC.  I would like 
to thank Heath group graduate students Kiwook Hwang and Chao Ma for helping during 
the latter stages of the NACS project.  Thanks to Ophir Vermesh for being so down-to-
v 
 
earth—you’ll be a very successful doctor!  I would like to thank Diane Robinson for 
processing all necessary paperwork (reimbursements!) and for all her direct statements 
and questions.  Thanks to Kevin Kan for managing the group facilities and providing 
financial advice.   
Thanks to my good friends from the Pierce lab, Harry Choi (whom I’ve known 
and worked with since my undergraduate days at UC Berkeley) and Suvir Venkataraman 
(the smoothest graduate student on campus) for their help in designing the orthogonal 
DNA sequences.    
 Because of the highly collaborative nature of the NSBCC, I would like to thank 
many collaborators at UCLA.  In particularly, I would like to thank Jenny Shu for help 
with protein expression and the Witte lab for their hospitality.  I would like to thank 
Begonya Comin-Anduix, Richard Koya and Thinle Chodon for preparing T cell samples 
for NACS.  I would like to thank my good friends from the Mischel Lab; Tiffany Huang 
for work on the GBM project, providing assistance with flow cytometry and conversing 
about people, dates, family history; Shawn Sarkaria for taking the leadership role in the 
GBM project, being a sounding board for scientific ideas, and his meticulous attention to 
detail.    
 Thanks to Bruz Marzolf at ISB for printing DNA microarrays and his promptness 
in response to problems and questions.          
 Lastly, I would like to acknowledge my family whose influence on my life I have 
yet to fully understand but has made me learn more about myself, and as a result lead a 
more genuine life.     
vi 
 
Abstract 
This thesis describes the development of DNA-encoded, multi-parametric, 
sensing platforms for informative cancer diagnostics.  In the first part of this thesis, I will 
present a technology called “DNA-encoded antibody library (DEAL).”  In this approach, 
computationally derived, orthogonal ssDNA sequences are conjugated to antibodies 
specific for protein targets and cell surface markers.  The resulting collection of 
conjugates is applied to a biological sample of interest, binds to their cognate antigens, 
and is detected after the complexes are hybridized to a glass substrate printed with 
spatially distinct complementary DNA sequences.  By using DNA assembly, the DEAL 
platform enables the simultaneous detection of the major classes of biological molecules, 
namely nucleic acids, proteins and cells.       
The second part of this thesis focuses on the development of a cell sorting 
platform that can detect antigen-specific T cells called “Nucleic Acid Cell Sorting 
(NACS).”  In NACS, ssDNA encoding is used to assemble peptide major 
histocompatability complexes (p/MHC) on glass substrates by hybridization to cDNA 
microarrays.  These assembled peptide/MHC microarrays are then used to sort mixed 
populations of antigen-specific T cells.  This spatially encoded scheme addresses the 
widespread desire for methods that allow the multiplexed detection of antigen-specific T 
cells.  The sensitivity and selectivity of NACS is similar to flow cytometry, demonstrated 
in key experiments with T cells derived from multiple sources, including endogenous and 
TCR-engineered T cells collected from cancer patients.  Finally, this platform is used to 
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monitor the persistence of cancer-specific T cells in peripheral blood collected from a 
patient undergoing T cellular immunotherapy.  
Lastly, a scheme for the detection of cell surface markers is presented.  In this 
approach, DEAL and NACS conjugates prepared with UV labile ssDNA oligonucleotides 
are allowed to bind to target cell samples in solution.  The ssDNA tags are released in 
solution by UV-induced photocleavage.  The presence and expression of the cognate 
antigen is determined by collecting the pool of reporter ssDNA tags followed by 
exponential amplification by PCR.  A DEAL conjugate specific for the oncogene EGFR 
was used to determine the expression level of EGFR in a low-passage brain tumor 
primary cell line.  The feasibility of using ssDNA-p/MHC complexes for detecting 
unique TCRs was also demonstrated.  Finally an experimental flow is described for 
integration with second generational high-throughput sequencing platforms for global 
and quantitative surface-ome profiling. 
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Chapter 1 
Introduction 
 
 
1.1 Complexity of human cancers 
Our current understanding of the molecular basis of cancer has been shaped by 
initial landmark studies demonstrating that cancer was caused by the deregulation of a 
few oncogenes or tumor suppressor genes (1, 2).  Identification of these genes and their 
encoded protein products has had a tremendous impact on molecular medicine, leading to 
effective targeted therapies for certain cancers.  For example, patients with chronic 
myelogenous leukemia (CML), a bone marrow derived cancer, express the fusion 
oncogene BCR-ABL that is effectively targeted by the kinase inhibitor imatinib mesylate 
(3–7).  In breast cancer, elevated levels of the membrane-bound receptor oncogene 
Her2/neu (ERBB2) predict response to the humanized monoclonal antibody therapeutic 
trastuzumab (8, 9).  The clinical effectiveness of targeted molecular therapies against 
certain types of cancer is a testament to the progress in cancer research and medicine. 
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It is becoming increasingly clear, however, that for the majority of metastatic 
cancers, a single or few genes is insufficient in predicting tumor behavior and does not 
represent all necessary and sufficient targets for molecular therapy.  Tumors are highly 
complex, dynamic, heterogeneous biological systems driven by series of genomic and 
epigenetic mutations that affect the genes controlling cell proliferation, survival, 
invasiveness and motility.  Typically, multiple primary genomic alterations are present 
within a single tumor with secondary mutations arising through genetic instability, 
enabling malignancies to develop resistance to drugs.  For example, the majority of lung 
adenocarcinomas that respond to epidermal growth factor receptor (EGFR) inhibitors 
(erlotinib and gefitinib) eventually develop resistance through selection of tumor cells 
expressing an EGFR variant containing a single amino acid mutation that confers drug 
resistance (10–12).  Pre-malignant tissue evolve in a multi-step process into tumors, each 
step highly sensitive to numerous interacting extracellular stimuli, including growth 
factors (13, 14), extracellular matrix proteases (15, 16), physiological stresses (e.g., low 
oxygen levels (17, 18)) and cytokines (19).  Many sources contribute to the tumor milieu, 
including non-tumor, stromal cells found in the local architecture (20, 21) and immune 
cells that have infiltrated the tumor microenvironment (19, 22, 23).  Thus for a typical 
malignancy, a large number of genomic, proteomic, physiological conditions, and 
supporting cell types are involved.   
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1.2 Diagnostic challenges presented by cancer 
One of the goals of cancer diagnostics is to detect and monitor biological 
elements that are representative of the interactions between the various components 
involved in a malignancy, and with the information be able to characterize the state of the 
system and/or generate network models with predictive features that would be of 
fundamental or therapeutic value (Figure 1.1).  The biological elements targeted are 
either directly involved in the malignancy (e.g. over expression of EGFR), or are 
byproducts of the process (e.g. circulating tumor DNA resulting from necrosis).    
Individually, they are referred to as biomarkers.  Currently, most FDA approved cancer 
diagnostic platforms focus on the detection of a single or few biomarkers and have been 
effective for several cancers for staging, monitoring, and prognostication (24).  This 
pauci-parameter approach, however, is being revised because of the molecular 
 
Figure 1.1  Numerous components of tumor biology must be queried for informative 
diagnostics.  Reciprocal interactions between the tumor microenvironment, tumor cell genome 
and tumor development drive the complexity of cancer, presenting challenges for multi-
parameter diagnostics.  Adapted from (36).  
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heterogeneity of cancer—the accuracy and coverage of diagnostic assays will be 
improved by adopting a multi-parameter systems approach, namely measure as many 
different biological elements as possible.  The motivation is that a collection of 
biomarkers would produce a molecular signature that would provide a higher level of 
sensitivity and specificity for staging, treatment and prognostication.         
A number of studies reported in the literature have shown that global profiling 
approaches are effective in characterizing cancer.  Differential gene expression studies 
have shown that diseased complex expression networks can be differentiated from their 
healthy counterparts and can be used to predict patient survival and response to cancer 
therapies (25−28).  Many of the proteins, genes and small molecules identified in these 
studies have spear-headed further investigations, including mechanistic studies (29) and 
the use of these targets as potential biomarkers (30−32).  Other global profiling 
approaches investigating genomic alterations (33−34) and proteomic alterations (30, 35) 
have also been reported, although for the latter, studies have been impeded by the lack of 
proteome wide capture agents and lack of technologies to capture all the proteomic 
functions concomitantly (36) (e.g. interactions involving protein-protein, protein-ligand, 
post-translational modifications).        
The adoption of a multi-parameter paradigm is compounded by the fact that most 
biological tissues collected from patients are small, making it challenging to execute 
large-scale analyses of the different classes of biological molecules (e.g. cells, genes, 
proteins, metabolites).  This has driven the miniaturization of many diagnostic assays into 
integrated biochips.  The benefits of developing biochips are severalfold.  First, 
integrated biochips are able to handle small amounts of tissue.  This is important in 
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interfacing with tumor tissue derived from skinny-needle biopsies and other minimally 
invasive diagnostic procedures.  Second, on-chip measurements can be highly parallel 
and multiplexed which is important in providing statistical certainty by repeated 
sampling.  Third, chip-based devices can be manufactured with well developed processes 
borrowed from mature engineering disciplines (e.g. semiconductor fabrication) and are 
typically compatible with a host of common instrumentation (e.g. fluorescent 
microscopy), lowering costs and increasing accessibility.   
 An example of a cancer diagnostic that has benefited from miniaturization is 
circulating tumor cell (CTC) detection.  CTCs are cells shed from primary tumors and are 
in circulation at low levels in blood.  The abundance of CTCs can be used to monitor the 
efficacy of cancer therapeutics.  Current technologies for CTC detection rely on bead-
based assays (37) but are plagued with low recoveries and low purity.  Recently, two 
chip-based, microfluidic devices have been reported which significantly increase 
recoveries and purities of CTC capture (38, 39).  The robustness of one biochip enabled 
the correlation of CTCs levels with decreased or increased tumor burden and the 
identification of mutations through genomic sequencing of CTCs collected from the 
device (40). 
1.3 DNA as an encoding element       
 The utility of DNA as a chemical material has reached into many areas of active 
research, including nanomaterials (41−43), DNA computing (44), automated machines 
(45), and molecular electronics (46).  In the arena of biological sensing involving mainly 
protein detection, technologies and platforms that have been developed include immuno-
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PCR (47), rolling circle amplification (48), proximity ligation (49), and nanoparticle-
based assays (50).  DNA-based, multiplexed assays in which multiple detection events 
are encoded and then decoded simultaenously include immunophenotyping using 
transcription (51) and self-assembled chemical libraries (52). 
 There are several reasons that makes DNA an attractive material and encoding 
element.  First, the exquisite specificity and favorable energetics of DNA base-pairing 
provides self-assembling properties, permiting complex 2-D and 3-D structures to be 
designed and predicted from linear primary sequences.  Second, analagous to its 
endogenous function, unique DNA sequences can be used to store information, scaling 
exponentially to the length N of the polymer.  Third, in its natural environment, DNA 
interfaces with a host of other biological elements which can be exploited for molecular 
level control.  For example, DNA can be specifically truncated with restriction 
endonucleases.  Fourth, the production of DNA oligonucleotides is trivial, owing in large 
part to chemical automation.  A wide variety of unnatural chemical handles (e.g. primary 
amines, thiols), readouts (e.g. fluorophores), and modified bases (e.g. locked nucleic 
acids) are available for incorporation into a primary sequence, expanding the utility and 
applications of the polymer.  Lastly, platforms to characterize DNA are robust, including 
sequencing, PCR, microarrays, and bioinformatic algorithms.  
1.4 Thesis overview  
 This thesis presents the development of chip-based, DNA-encoded technologies 
to address the current multi-parameter challenges associated with in vitro cancer 
diagnostics.  In Chapter 2, I will begin by introducing the development of an approach 
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called DNA-Encoded Antibody Libaries (DEAL) in which computationally derived, 
orthogonal ssDNA tags are conjugated to an antibody library where every antibody-
specificity is uniquely encoded with a distinct ssDNA sequence.  A library of DEAL 
conjugates is exposed to a biological sample, bind to their cognate antigen, and decoded 
spatially on a glass substrate printed with the complementary DNA sequences.  I 
demonstrate the DEAL technique for;  (1) the rapid detection of multiple proteins within 
a single microfluidic channel, and with the additional step of electroless amplification of 
gold-nanoparticle labeled secondary antibodies, establish a detection limit of 10 fM for 
the protein IL-2; (2) the multiplexed, on-chip sorting of both immortalized cell lines and 
primary immune cells; and (3) the co-detection of ssDNAs, proteins, and cell populations 
on the same platform.  By using a common assembly molecule, DEAL meets the 
diagnostic need for multi-parameter platforms able to manipulate and detect major 
subtypes of biological molecules (genes, proteins, cell membrane-bound markers).  
Moreover, this technique is fully integrable with fluidics, enabling the processing of 
small tissue samples.  Chapter 2 has been taken in part from © J. Am. Chem. Soc. 2007, 
129(7), 1959−67. 
 Chapter 3 extends and develops the concept of cell sorting with DNA tags in the 
context of an important immunological problem with clinical implications for cancer 
therapy, namely that of detecting antigen-specific T cells.  Through genetic 
recombination, T cells are capable of recognizing and engaging to cells presenting 
processed antigenic fragments, including antigens presented by cancer cells.  The ability 
of T cells to cull target populations of cells has been exploited as an experimental cancer 
therapy by infusing patients with augmented and activated T cells specific for cancer 
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associated antigens (53) with documented T cell-induced tumor regression in subsets of 
patients with metastatic cancers (54, 55). 
Despite these promising trials, T cellular immunotherapy is difficult to 
characterize fully because of technological bottlenecks that do not allow the multi-
parametric analysis of different antigen-specific T cells in small numbers.  With the goal 
of highly multiplexed T cell detection, Chapter 3 will introduce technique called "Nucleic 
Acid Cell Sorting (NACS)" in which single-stranded DNA oligomers conjugated site-
specifically to p/MHC tetramers are employed to immobilize p/MHC tetramers via 
hybridization to a complementary-printed substrate.  Fully assembled p/MHC arrays are 
used to detect and enumerate T cells captured from cellular suspensions, including 
primary human T cells collected from cancer patients.  Importantly, T cell array binding 
is optimized by utilizing cysteine-engineered streptavidin (SAC) for ssDNA-p/MHC 
tetramer production, resulting in NACS p/MHC arrays that outperform conventional 
spotted arrays assessed by performance standards such as reproducibility and 
homogeneity.  The versatility of using DNA tags is also exploited to enable selective 
detachment of T cells with restriction endonucleases.  Demonstrative experiments 
regarding NACS sensitivity, multiplexing and limit of detection are performed with cell 
lines and with T cells isolated from cancer patients.  Lastly, I show an important clinical 
application of this technology by monitoring the presence and abundance of a cancer-
specific T cell population collected from a melanoma patient receiving cellular 
immunotherapy.  Chapter 3 has been taken in part from © J. Am. Chem. Soc., 2009, in 
press.       
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Cell surface proteins constitute an important subset of the cellular proteome, as 
these proteins are frequent targeted for molecular therapy, staging and for directing 
therapies.  Chapter 4 presents current work on detecting cell membrane-bound proteins 
by amplification of encoded ssDNA tags.  In this approach, DEAL/NACS conjugates are 
synthesized with photolabile ssDNA tags.  Whereas in previous demonstrations, the 
ssDNA tags were employed as molecular tethers, in the cellular barcoding approach, the 
ssDNA tags are used as reporter molecules.  After staining a population of cells with a 
library of DEAL/NACS conjuates, the ssDNA tags are released into solution via UV 
cleavage and collected for analysis by PCR.  The quantity of each unique ssDNA tag 
directly correlates to the  presence and expression of the targeted cell surface markers.  I 
demonstrate that this concept by detecting EGFR over-expression from a low-passage 
brain cancer cell line (GBM1600) relative to EGFR null Jurkat human T cells.  In 
addition, I show that different TCR specificities can be differentiated by this technique by 
using NACS conjugates to detect the presence of a TCR specific for a melanoma-
associated cancer antigen, MART-1.  Lastly, experimental details will be presented to 
interface with second generation sequencing platforms for high throughput and 
quantitative analysis of the reporter barcodes for global cell surface-ome profiling.      
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Chapter 2 
DNA-Encoded Antibody Libraries:  A Unified 
Platform for Multiplexed Cell Sorting and 
Detection of Genes and Proteins  
 
 
 
2.1 Introduction 
Global genomic and proteomic analyses of tissues are impacting our molecular-
level understanding of many human cancers.  Particularly informative are studies that 
integrate both gene expression and proteomic data.  Such multi-parameter data sets are 
beginning to reveal the perturbed regulatory networks which define the onset and 
progression of cancers (1–5).  This new picture of cancer, and the emergence of 
promising new cancer drugs (6, 7) are placing new demands on clinical pathology (8).  
For example, traditional pathology practices (i.e. microscopic analysis of tissues) do not 
distinguish potential responders from non-responders for the new cancer molecular 
therapeutics (9).  Recent examples exist in which pauciparameter molecular 
measurements are being employed to identify potential responders to at least two 
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therapauetics (10–13).  However, it is unlikely that single-parameter measurements will 
be the norm.  Instead, the coupling of molecular diagnostics with molecular therapeutics 
will eventually require measurements of a multi-parameter (e.g. cells, mRNAs and 
proteins) biomarker panel that can be used to direct patients to appropriate therapies or 
combination therapies. 
Currently, the measurement of a multi-parameter panel of biomarkers from 
diseased tissues requires combinations of microscopic analysis, microarray data (14), 
immunohistochemical staining, western blots (8), and other methods.  The collected data 
is integrated together within some model for the disease, such as a cancer pathway model 
(15), to generate a diagnosis.  Currently, performing these various measurements requires 
a surgically resected tissue sample.  The heterogeneity of such biopsies can lead to 
significant sampling errors since various measurements of cells, mRNAs, and proteins 
are each executed from different regions of the tissue. 
In this chapter, the DNA-encoded antibody library, or DEAL, approach (Figure 
2.1), is described as an important step towards executing a true multi-parameter analysis 
(cells, mRNAs and proteins) from the same microscopic region of tissue.  We report on 
several key demonstrations for achieving this goal, including the rapid detection of 
proteins and protein panels over a broad dynamic range and with a detection limit of <10 
femtoM; the sorting of immortal and primary lymphocyte populations; the co-detection 
of cells, cDNAs, and proteins on the same platform, and the integration of our multi-
parameter platform with microfluidic techniques. 
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Figure 2.1  Illustration of the DEAL method for cell sorting and co-detection of proteins 
and cDNAs (mRNAs).  Unique DNA-Antibody conjugates are prepared and then combined into 
a single solution where they recognize cognate antigens, including cell surface markers and 
proteins of interest. When introduced onto a conventional DNA microarray, parallel self 
assembly, according to Watson-Crick base pairing, localizes the bound species to a specific 
spatial location allowing for highly multiplexed multi-parameter analysis. 
A key issue involved with a microfluidics-based multi-parameter assay is that the 
measurement of different classes of biomolecules (or cells) typically requires different 
surface chemistries, and not all of them are compatible with each other or the fabrication 
steps associated with building the microfluidics circuitry.  Conventional antibody arrays 
for protein detection or for panning cells (16) require immobilization of the antibody onto 
aldehyde, epoxy, maleimide, or hydrophobic solid supports (17–20).  It is often difficult 
to preserve folded (active) antibody conformations due to surface induced denaturation 
which depends on many variables including pH, ionic strength, temperature and 
concentration (21–23).  This has spurred the development of alternative approaches to 
preserve the native conformation of proteins including 3-dimensional matrixes like 
hydrogels, and polyacrylamide (24, 25), cutinase-directed antibody immobilization onto 
SAMs (26), and the coupling of biotinylated antibodies onto streptavidin coated surfaces 
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(27).  In addition, the arrays need to remain hydrated throughout the entire manufacturing 
process in order to prevent protein denaturation (18).  DNA microarrays, on the other 
hand, are typically electrostatically absorbed (via spotting) unto amine surfaces.  One 
option for detecting both DNA and proteins on the same slide would be to pattern both 
functional groups used to immobilize DNA and protein onto the same substrate, although 
this would significantly increase the complexity and engineering of the system.  
Alternatively, a compatible surface may be an activated ester glass slide to which amine-
DNA and proteins can both covalently attach.  However, we have found that the loading 
capacity of these slides for DNA is diminished, resulting in poor signal intensity when 
compared with DNA printed on conventionally prepared amine slides.  In addition, 
unreacted esters are hydrolyzed back to carboxylic acids, which are negatively charged at 
normal hybridization buffers (pH 7), electrostatically reducing the DNA interaction.  
Moreover, to interrogate cells and proteins, the best surface to reduce non specific 
binding of cells while maintaining full antibody functionality is acrylamide (28, 29), 
which is incompatible with DNA. 
By using DNA as a common assembly strategy for cells, cDNAs, and proteins, we 
are able to optimize the substrate conditions for high DNA loading onto the spotted 
substrates, and for complementary DNA loading on the antibodies.  This leads to highly 
sensitive sandwich assays for protein detection, as well as high efficiency cell sorting 
(compared with traditional panning).  We also find that non-selective binding 
(biofouling) of proteins to DNA-coated surfaces is reduced.  Importantly, DNA coated 
surfaces can be dried out, stored or heated (overnight at 80o C), thus making them 
compatible with robust microfluidics fabrication. 
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DNA-labeled antibodies have been previously used to detect proteins (30–32), 
largely with the pendant oligomers serving as immuno-PCR tags (33, 34).  DNA-tags 
have been used to direct the localization of proteins allowing assays to take advantage of 
spatial encoding, via several different read-out strategies (35–37).  Conventional multi-
well ELISA assays are capable of quantitating multiple proteins, but typically require 
separate sample volumes for each parameter. Optical multiplexing can expand this, but is 
limited by the number of non-spectrally overlapping chromophores.  Spatial 
multiplexing, such as is used with DEAL, allows for the execution of many 
measurements on a small sample, since the number of different measurements is limited 
only by the patterning method utilized to prepare the cDNA array.  Spotted antibody 
arrays (18), while potentially useful for protein detection and/or cell sorting, are not 
easily adaptable towards microfluidics-based assays, since the microfabrication process 
for preparing robust microfluidics devices often involves physical conditions that will 
damage the antibodies. Complementary DNA arrays are robust to such fabrication 
conditions.  
2.2 Experimental Methods  
2.2.1 DNA sequences for spatial encoding  
All DNA strands were purchased with a 5’-amino modification from the Midland 
Certified Reagent company.  Sequences for sequences A1, B1, C1 and their respective 
complements A1’, B1’ and C1’ are given in Table 2.1.  Computationally derived 
sequences, designated as A3, B3, C3 and their respective complements A3’, B3’ and C3’ 
were designed following the paradigm outlined by Dirks et al. (38).  Example input files 
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and output sequences can be found in the Appendix A.  The sequences are reported in 
Table 2.1.      
Table 2.1  DNA sequences for spatial encoding
 
Name Sequence
 
A1 5’-NH2-AAAAAAAAAACGTGACATCATGCATG-3’ 
A1’ 3’-GCACTGTAGTACGTACAAAAAAAAAA-NH2-5’ 
B1 5’-NH2-AAAAAAAAAAGGATTCGCATACCAGT-3’ 
B1’ 3’-CCTAAGCGTATGGTCAAAAAAAAAAA-NH2-5’ 
C1 5’-NH2-AAAAAAAAAATGGACGCATTGCACAT-3’ 
C1’ 3’-ACCTGCGTAACGTGTAAAAAAAAAAA-NH2-5’ 
A3 5’-NH2-AAA AAA AAA A AT CCT GGA GCT AAG TCC GTA 
A3’ 5'-NH2- AAA AAA AAA ATA CGG ACT TAG CTC CAG GAT 
B3 5'-NH2-AAA AAA AAA  AGC CTC ATT GAA TCA TGC CTA 
B3’ 5'-NH2-AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA 
C3 5'-NH2-AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA 
C3’ 5'-NH2-AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC 
 
2.2.2 DNA antibody conjugation  
AlexaFluor 488, 594, and 647-labeled polyclonal Goat anti-Human IgGs were 
purchased from Invitrogen. Monoclonal Rabbit anti-Human Interleukin-4 (clone: 8D4-8), 
non-fluorescent and APC-labeled Rabbit anti-Human Tumor Necrosis Factor-α (clones: 
MAb1 and MAb11, respectively), and non-fluorescent and PE-labeled Rabbit anti-
Human Interferon-γ (clones: NIB42 and 4S.B3, respectively) were all purchased from 
eBioscience.  Non-fluorescent and biotin-labeled mouse anti-Human Interleukin-2 
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(clones: 5344.111 and B33-2, respectively) were purchased from BD Biosciences.  Prior 
to use, all antibodies were desalted, buffer exchanged to pH 7.4 PBS and concentrated to 
~ 1mg/ml using 3000 MWCO spin filters (Millipore).  Succinimidyl 4-
hydrazinonicotinate acetone hydrazone in DMF (SANH, Solulink) was added to the 
antibodies at variable molar excess of (1000:1 to 5:1) of SANH to antibody.  In this way 
the number of hydrazide groups introduced to the antibodies was varied.  Separately, 
succinimidyl 4-formylbenzoate in DMF (SFB, Solulink) was added at a 20-fold molar 
excess to 5’aminated 26mer oligomers in PBS.  This ratio of SFB to DNA ensured 
complete reaction of the 5’ amine groups to yield 5’ aldehydes.  No further improvement 
in yield was observed for either the antibody and oligonucleotide coupling reactions after 
4 hours at room temperature.  Excess SANH and SFB were removed and samples 
buffered exchanged to pH 6.0 citrate buffer using protein desalting spin columns (Pierce).  
A 20-fold excess of derivatized DNA was then combined with the antibody and allowed 
to react overnight at room temperature.  Non-coupled DNA was removed with size 
exclusion spin columns (Bio-Gel P-30, Bio-Rad) or purified using a Pharmacia Superdex 
200 gel filtration column at 0.5 ml/min isocratic flow of PBS.  The synthesis of DNA-
antibody conjugates was verified by non-reducing 7.5% Tris-HCl SDS-PAGE at relaxed 
denaturing conditions of 60oC for 5 minutes, and visualized with a Molecular Imager FX 
gel scanner (Bio-Rad).  Conjugation reactions involving fluorescent antibodies or 
fluorescentl oligonucleotides were imaged similarly using appropriate excitation and 
emission filters.   
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2.2.3 Microarray Fabrication   
DNA microarrays were printed via standard methods by the microarray facility at 
the Institute for Systems Biology (ISB—Seattle, WA) onto amine-coated glass slides.  
Typical spot size and spacing were 150 and 500 μm, respectively.  Poly-lysine slides 
were made in house.  Blank glass slides were cleaned with IPA and water in a sonication 
bath for 10 minutes each.  They were then treated with oxygen plasma at 150 W for 60 
sec., and then quickly dipped into DI water to produce a silanol terminated, highly 
hydrophilic surface. After drying them with a nitrogen gun, poly-L-lysine solution 
(Sigma P8920, 0.1% w/v, without dilution) was applied to the plasma treated surfaces for 
15 minutes, and then rinsed off with DI water for several seconds. Finally, these treated 
slides were baked at 60oC for 1hr.  These slides were then sent to ISB and printed as 
described above. 
2.2.4 Fabrication of Microfluidic Devices      
Microfluidic channels were fabricated from polydimethylsiloxane (PDMS) using 
conventional soft lithographic techniques.  The goal was to fabricate robust microfluidics 
channels that could be disassembled after the surface assays were complete for optical 
analysis.  Master molds were made photolithographically from a high resolution 
transparency mask (CadArt) so that the resulting fluidic network consisted of 20 parallel 
channels each having a cross-sectional profile of 10 x 600 μm and were 2 cm long.  This 
corresponds to channel volumes of 120 nl.  A silicone elastomer (Dow Corning Sylgard 
184) was mixed and poured on top of the mold.  After curing, the PDMS was removed 
from the mold and sample inlet and outlet ports punched with a 20 gauge steel pin 
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(Technical Innovations).  The microfluidic channels were then aligned on top of the 
microarray and bonded to the substrate in an 80oC oven overnight.   
2.2.5 1o Antibody Microarray Generation and DEAL-Based Immunoassays  
Antibody microarrays were generated by first blocking the DNA slide with 0.1% 
BSA in 3x SSC for 30 minutes at 37oC.  The slides were washed with dH2O and blown 
dry.  A 30 μl solution containing DNA-antibody conjugates (3x SSC, 0.1% SDS, 0.1% 
BSA, 15 ng/μl of each conjugate) was sandwiched to the array with a microscope slide, 
and incubated at 37oC for 4 hours.  Arrays were then washed first in 1x SSC, 0.05% SDS 
at 37oC with gentle agitation, then at 0.2x SSC, then finally at 0.05x SSC.  The slides 
were blown dry and scanned with a Gene Pix 4200 A two-color array scanner (Axon 
Instruments).  For immunoassays, the DNA-encoded 1o antibody (15 ng/μl), antigen (3 
ng/μl) and fluorescent 2o antibody (0.5 ng/μl) were combined in a single tube.  After 2 
hour incubation at 37oC, the formed antibody-antigen-antibody complexes were 
introduced to the microarrays as described above. Subsequent wash steps and 
visualization were identical. 
2.2.6 Microfluidic-based assay procedures 
Microfluidic devices were interfaced with 23 gauge steel pins and Tygon tubing 
to allow pneumatically controlled flow rates of ~0.5 μl/min.  The assays were performed 
in Tris Buffered Saline (TBS), which was found to be better than 1x SSC and PBS.  Each 
channel was blocked with 1.0% BSA in TBS prior to exposure to DNA-antibody 
conjugates or immunoassay pairs for 10 minutes under flowing conditions.  After a 10 
minute exposure to conjugates or antigens under flowing conditions, channels were 
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washed with buffer for 2 minutes and the microfluidics disassembled from the glass slide 
in order to be scanned.  Immediately prior to imaging, the entire slide was briefly rinsed 
in TBS, blown dry and imaged on an array scanner as described above.  For the human 
IL-2 concentration series, primary DNA-antibody conjugates were laid down first on the 
surface, before exposure to antigen and secondary antibody.  This was necessary because 
at lower concentrations of antigen, the signals decrease, due to the high ratio of antigen-
unbound primary antibody competing with antigen-bound primary for hybridization to 
the DNA array.  By first exposing the array to the primary DNA-antibody conjugate, 
excesses were washed away before subsequent exposure to antigen and secondary 
antibody, increasing signal.    
2.2.7 Microfluidic Au amplification methods   
Microfluidics-based Au amplification experiments were performed in a similar 
manner, with the notable exception that a biotin-secondary antibody was used instead of a 
fluorescently labeled antibody.  Subsequently, Au-streptavidin (Nanoprobes) was 
introduced into each channel (3ng/μl) for 10 minutes, after which the channels were 
thoroughly rinsed with buffer.  After removal of the PDMS, the entire slide was then 
amplified with gold enhancer kit (Nanoprobes) according to manufacturer’s protocol. 
2.2.8 Analysis of DNA-encoded antibodies by flow cytometry   
VL3 and A-20 cells were incubated for 20 min. on ice with 0.5 μg of FITC-
conjugated Rat Anti-Mouse CD90.2 (Thy1.2, BD Pharmingen, clone 30-H12, catalog # 
553012) in 100 μL PBS-3% FCS. Cells were also incubated with equimolar amounts of 
α-CD90.2/FITC-DNA conjugates characterized by various FITC-DNA loadings. Cells 
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were washed once with PBS-3% FCS and then were analyzed by flow cytometry on a BD 
FACSCantoTM instrument running the BD FACSDivaTM software. 
2.2.9 Cell capture, separation, and sorting methods   
Two murine cell lines, VL-3 T cells (thymic lymphoma line (39)) and A20 B cells 
(mouse B cell lymphoma (40), purchased from ATCC) were engineered to express mRFP 
and EGFP, respectively, using standard retroviral transduction protocols.  Antibodies 
against surface markers for each of these cell lines, α-CD90.2 for VL-3 and α-B220 for 
A20 (eBioscience), were encoded as described above with DNA strands A1’ and B1’, 
respectively. 
For sorting experiments, cells were passaged to fresh culture media [RPMI 1640 
(ATCC) supplemented with 10 % fetal bovine serum, 0.1 mM non-essential amino acids 
and 0.05 mM β-mercaptoethanol at a concentration of 106 cells/100 μl media and 
incubated with DNA-antibody conjugate (0.5 μg/100 μl) for 30 minutes on ice.  Excess 
conjugate was removed from the supernatant after centrifugation, after which cells were 
resuspended in fresh media.  Prior to cell incubation the microarray slide was passivated, 
to reduce non-specific cell adhesion, by reaction of the residual amine groups with 
methyl-PEO12-NHS ester (Pierce) 10 mM in pH = 7.4 PBS for  4 hours at room 
temperature.  Cells were spread evenly across the microarray surface and allowed to 
localize for one hour on ice.  After this period, non-adherent cells were removed with 
gentle washing with room temperature Tris-buffered saline solution including 1 mM 
MgCl2.  Cell enrichment experiments were performed identically except that all 
incubation steps were performed in the presence of a 1:1 mixture of both T- and B-cells 
(each at 106/100 μl). 
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Primary CD4+ and CD8+ T cells were purified from EGFP and dsRed transgenic 
mice (obtained from Jackson Laboratories), respectively, using standard magnetic bead 
negative selection protocols and the BD IMagTM cell separation system. Prior to DEAL-
based fractionation, the purity of these populations was analyzed by FACS and found to 
be greater than 80%. 
Simultaneous cell, gene and protein experiments were performed similarly to 
those as previously described on a PEGylated microarray substrate.  Briefly, GFP-
expressing B cells (106/100 μl) were located on B1 spots after labeling with α-B220-B1’ 
(0.5 μg/100μl).  Following removal of non-adherent cells, a TNF-α ELISA pair with C1’-
encoded 1o and APC-labeled 2o antibodies were introduced along with 0.5 ng/μl  FITC-
labeled A1’ and allowed to hybridize for a period of 30 minutes at room temperature.  
The slide was then rinsed with TBS+MgCl2 and visualized via brightfield and 
fluorescence microscopy.  
Homogeneous and panning cell experiments were performed in parallel.  For the 
homogenous cell capture process, 5x106 Jurkats (ATCC) suspended in 1 ml of RPMI 
media along with 5 μg of α-CD3/C3’ conjugates and incubated on ice for 1 hour.  Excess 
conjugates were removed by centrifugation and the Jurkats were resuspended into 200 μl 
of fresh media before exposure to the DNA microarray.  After 1 hour incubation on ice, 
the slides were rinsed gently with TBS.  The cell panning experiments were performed in 
parallel; 5 ug of α-CD3/C3’ conjugate in 1 ml RPMI media was incubated on a 
microarray for 1 hour on ice before rinsing in 0.5x PBS, then deionized water.  The slide 
was not blown dry, but gently tapped on the side to remove the majority of the excess 
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solution, keeping the array hydrated.  Jurkats (5x106/200 μL) were immediately placed 
on the array for one hour on ice.  Subsequent wash and visualization steps are identical. 
2.3 Results and Discussion  
2.3.1 In silico design of orthogonal DNA oligonucleotides 
 The pendant DNA oligonucleotides were designed de novo in order to minimize 
inter- and intra-strand cross hybridization.  We followed the paradigm outlined by Dirks 
et al. (38) to computationally derive a set of orthogonal 30mers.  These sequences were 
designed with a polyA10 sequence followed by a variable 20mer encoding region.  The 
polyA10 stretch was incorporated to provide molecular flexibility and to prevent steric 
hindrance between the 20mer encoding region and the antigen binding domains of the 
antibody after conjugation.  Three sequences, designated A3–C3 were generated using 
this approach and were tested empirically.  Identical cDNA arrays printed with A3, B3, 
and C3 were probed with fluorescent complements A3’ (green), A3’+B3’ (red), and 
A3’+C3’ (red).  Minimal noise was observed between the probe sequences and 
noncomplementary spots (Figure 2.2).  We performed initial DEAL experiments with 
sequences A1–C1 before determining that a rational design of the sequences was 
necessary to minimize noise.  Therefore the majority of the experiments outlined in this 
chapter are presented using sequences A1–C1.   
One advantage of using DNA oligonucleotides as molecular addresses is 
modularity.  One working orthogonal set of sequences that has been experimentally 
validated can be used interchangeably with distinct sets of antibody libraries without 
modification of the underlying cDNA microarray.  This feature allows  
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Figure 2.2  DNA sequences derived from computation minimize cross hybridization.  (A)  
Fluorescent scans of three identical cDNA arrays probed with different combinations of 
fluorescent complementary strands.  (B)  Intensity profiles of the arrays   
 
2.3.2 Generation of DNA-Antibody conjugates 
Chemically modified antibodies to aid in protein immobilization and/or detection 
are nearly universal for use in immunoassays.  Such labeling introduces the risk of 
detrimentally affecting antibody function; however, that risk can be reduced by 
minimizing the size, and thus the steric hindrance, of the pendant moieties.  With this in 
mind, we employed a covalent conjugation strategy in which 5’-aminated single-stranded 
oligonucleotides were coupled to antibodies via a hydrazone linkage (31), as shown in 
Scheme 2.  Using commercially available reagents, an aldehyde functionality was 
introduced to the 5’-aminated oligonucleotide via succinimide chemistry.  Similarly, a 
hydrazide moiety was introduced via reaction with the lysine side chains of the respective 
antibody.  DNA-antibody conjugate formation was then facilitated via stoichiometric 
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hydrazone bond formation between the aldehyde and hydrazide functionalities.  
Conjugate formation and control over DNA-loading (41) was verified by PAGE 
electrophoresis, as shown in Figure 2.3.  
 
Figure 2.3  Illustration of the two step coupling strategy utilized to prepare DEAL 
antibodies.  In parallel, hydrazide groups are introduced onto a monoclonal antibody and 5’ 
aldehyde modified single-stranded DNA is prepared from 5’ aminated oligomers.  When 
combined, hydrazone bonds are formed, linking the ssDNA to the antibody. At bottom right is a 
gel mobility shift assay showing varied oligomer (strand A1’) loading unto α-human IL-4. By 
varying the stoichiometric ratios of SANH to antibody (lanes I-IV corresponds to 300:1, 100:1, 
50:1, 25:1 respectively), the average number of attached oligonucleotides can be controlled.  
Clearly the adverse steric effects of tagging antibodies with oligonucleotides are 
of concern when performing various assays, such as the immunoassays and cell 
sorting/capture experiments described herein.  For this reason, we investigated the ability 
of DNA-encoded antibodies to retain recognition of cell surface markers, as visualized by 
fluorescence activated cell sorting (FACS).  By using a fluorophore covalently tagged to 
the DNA, but not the antibody, FACS was used to optimize DNA-loading for the DEAL 
conjugates.  For the analysis, 5’ aminated, 3’ FITC-labeled DNA as tagged unto α-
CD90.2 antibodies at various stoichiometric ratios of SANH to antibody (5:1, 25:1, 50:1, 
100:1, 300:1).  This produced, on average, conjugates with 1, 2, 3, 4–5 and 6–7 strands of 
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FITC-DNA respectively, as measured by gel mobility shift assays (Figure 2.3).  These 
conjugates were tested for their ability to bind to the T cell line VL3 (CD90.2 
expressing), by monitoring the FITC fluorescence with the flow cytometer.  The B cell 
line A20 (CD90.2 negative) was used as a negative control.  The performance of the 
conjugates was also compared with commercially available FITC α-CD90.2.  The results 
are shown in Figure 2.4.  The histogram of the mean fluorescent intensities for various 
FITC-DNA loadings shows that fluorescence increases are roughly linear when the 
number of DNA strands is increased from 1 to 2 to 3, corresponding to 1, 2 and 3 
chromophores (1 per strand).  At higher loadings, the increase in fluorescence first 
plateaus (4–5 oligomers) and then decreases up to the highest loading (6–7 oligomers).  
Thus, excess DNA labels (4–7 oligomers) did sterically reduce the ability of antibodies to 
recognize cell surface markers.   Optimal loading for cell surface marker recognition was 
achieved with antibodies synthesized with the 50:1 SANH:antibody ratio, corresponding 
to approximately three DNA strands per antibody.  Subsequent cell sorting experiments 
were performed in consideration of this observation.  When compared with the FITC α-
CD90.2 control, the DNA antibody conjugates had reduced fluorescence by a factor of 10 
and slightly higher nonspecific binding to A20 cells.   
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Figure 2.4  Optimization of DNA loading of DEAL antibodies for cell surface marker 
recognition.  (a) FACS plot comparing α-CD90.2/FITC-DNA conjugates with the commercially 
available FITC α-CD90.2 antibody (no DNA).  The conjugates bind to VL3 cells (100%) with 
minimal non-specific interactions with A20 (1.3%).  When compared with FITC α-CD90.2, the 
overall fluorescent intensities are lower by a factor of 10, with slightly higher non-specific 
binding to A20.  (b)  Histogram of the mean fluorescent intensities for various FITC-DNA 
loadings.  Fluorescence increases are roughly linear when the number of DNA strands is 
increased from 1 to 2 to 3, corresponding to the 1, 2 and 3 chromophores (1 per strand).  For 
higher loadings, the fluorescence plateaus and then decreases.   
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This could be due to a couple of reasons.  A likely factor is that the stoichiometric 
ratio of fluorophore to antibody for the DEAL conjugates versus the commercial antibody 
is different.  For the DEAL conjugates, each strand of DNA is attached to one 
fluorophore only (i.e. conjugates with one DNA strand has a fluorophore to antibody 
ratio of 1:1) whereas the commercial antibodies generally have more than one 
fluorophore per antibody (i.e. fluorescent antibodies have a fluorophore to antibody ratio 
>1).  Thus the factor of 10 less fluorescence should not be strictly interpreted as a 10x 
reduction in the binding affinity of the DEAL conjugates, although it is possible that the 
oligomer steric effects discussed earlier do account for some reduction in relative 
fluorescence intensity.  Direct measurement of the affinity of the DEAL conjugate 
compared with the corresponding unmodified antibody using methods like Surface 
Plasmon Resonance (SPR) will be more conclusive. 
 
2.3.3 Multiplexed protein detection by DEAL 
We demonstrated the DEAL concept for spatially localizing antibodies using 
three identical goat anti-human IgGs, each bearing a different molecular fluorophore and 
each encoded with a unique DNA strand.  A solution containing all three antibodies was 
then introduced onto a microarray spotted with complementary oligonucleotides.  After a 
two hour hybridization period and substrate rinse, the antibodies self-assembled 
according to Watson-Crick base-pairing, converting the >900 spot complementary DNA 
chip into a multi-element antibody microarray (Figure 2.5).  This observation implied 
that quite large antibody arrays can be assembled in similar fashion.  
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Figure 2.5  Spatially encoded protein array.  Three biochemically identical goat α-human IgG 
(labeled with Alexa488, Alexa594, or Alexa 647 dyes) were tagged with oligos A1’, B1’ and C1’ 
respectively.  After a 2 hour incubation, antibody/DNA conjugates were localized to specific sites 
dictated by the underlying DNA microarray.  Scale bar corresponds to 1 mm. 
 
The ultimate size of any protein array, however, will likely be limited by 
interference from non-specific binding of proteins.  In an effort to visualize the 
contributions of non-specific binding, three antibodies were similarly introduced onto a 
microarray: two antibodies having complementary DNA-labeling spotted 
oligonucleotides and a third unmodified antibody (Fig. 2.6).  For demonstration purposes, 
the slide was not thoroughly rinsed following hybridization and accordingly a high 
background signal due to non-specific adsorption of non-encoded fluorescently-labeled 
antibody was observed.  The spotted nucleotide regions, to which no antibody was 
chemically encoded, displayed much less non-specifically attached protein, implying that 
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DNA greatly diminishes active area biofouling.  Such retardation of biofouling is 
reminiscent of substrates that are functionalized with polyethyleneglycol (PEG) (41–43).  
By analogy with postulated mechanisms associated with PEG (44–46), we hypothesize 
that the hydrophilic nature of the spotted oligonucleotides minimizes interactions with 
hydrophobic portions of proteins often exposed during non-specific adsorption.  
Conjugate hybridization experiments were also carried out within 5 degrees of the 
calculated duplex melting temperatures, taking advantage of Watson-Crick stringencies 
and thus diminishing non-complementary DNA interactions.  In any case, this reduced 
biofouling means that the DEAL method can likely be harnessed to detect reasonably 
large panels of proteins within a single environment.  
 
 
Figure 2.6  Illustration of the resistance of the DEAL approach towards non-specific protein 
absorption.  A microarray was simultaneously exposed to goat α-human IgG-Alexa488/A1’, 
goat α-human IgG-Alexa647/C1’ DEAL conjugates and goat α-human IgG-Alexa594 with no 
pendant DNA.  When the arrays were not fully blocked and/or rinsed, non-specific binding was 
observed on the surface of the glass slide, but not on the non-complementary spots of printed 
DNA, i.e., spot B1 did not have fluorescence from non-complementary IgG conjugates nor did it 
exhibit fluorescence from proteins not encoded with DNA (goat α-human IgG-Alexa594).  Scale 
bar corresponds to 1mm. 
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2.3.4 Detection of multiple proteins within a single microfluidic channel   
Microfluidic-based assays offer advantages such as reduced sample and reagent 
volumes, and shortened assay times (47).  For example, under certain operational 
conditions, the surface binding assay kinetics are primarily determined by the analyte 
(protein) concentration and the analyte/antigen binding affinity, rather than by diffusion 
(48).  We evaluated a microfluidics-based DEAL approach by bonding a 
polydimethylsiloxane (PDMS)-based microfluidic channel on top of a DNA microarray 
(Figure 2.7A).  We initially performed a multiplexed antibody localization experiment, 
similar to that described above.  The antibody conjugates self-assembled at precise spatial 
locations encoded by the pendant oligonucleotide in <10 minutes (Figure 2.7B), 
consistent with the time scales reported on DNA hybridization in microfluidics (49–51).  
 
Figure 2.7  Protein array assembled in microfluidics in 10 minutes.  (A)  Picture of PDMS 
microfluidic device encapsulated a DNA array (yellow box) (B) Two goat α-human IgG (labeled 
with Alexa594 or Alexa 647) were tagged with oligos A1’ and B1’ respectively and introduced 
into a microfluidic device bonded on top of a DNA microarray with corresponding 
complementary strands A1 and B1 along with non-complementary strand C1.  No DEAL 
conjugate encoded to spot C1 was added.  After flowing at ~0.5 μl/min for 10 minutes, the 
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microfluidic PDMS slab was removed and the glass slide imaged.  The dashed lines delineate 
separate microfluidic channels of 600 μm width.   
 
To validate the DEAL strategy for protein detection, we utilized encoded 
antibodies to detect cognate antigens in a variant of standard immunoassays.  In a 
standard immunoassay (52), a primary antibody is adsorbed onto a solid support, 
followed by the sequential introduction and incubation of the antigen-containing sample 
and secondary labeled “read-out” antibody, with rinsing steps in between.  In order to 
simplify this conventional five step immunoassay, we reasoned that the encoding power 
of the DEAL antibodies could serve to position the entire sandwich complex to the 
appropriate location for multiplexed readout, reducing the assay to a single step.  To test 
this concept, in the same solution, a non-fluorescent, DNA-encoded 1o antibody was 
combined with antigen and a fluorescently-labeled (no DNA) 2o antibody.  Under these 
conditions, a fluorescent signal will be spatially encoded only if an antibody-antigen-
antibody sandwich is successfully formed in homogeneous solution and localized onto 
the microarray.  Upon introduction of DNA-encoded antibodies against two cytokines, 
human IFN-γ and TNF-α, cognate antigens and fluorescently-labeled 20 antibodies, the 
DEAL sandwich assays self-assembled to their specific spatial locations where they were 
detected, as shown in Figure 2.8.  This multi-protein immunoassay also took 10 minutes 
to complete.   
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Figure 2.8  DNA-templated protein immunoassays executed within microfluidic channels.  
The 600 μm micrometer wide channels are delineated with white dashed lines. (a). Two 
parameter DEAL immunoassay showing the detection of IFN-γ at spot A1 with a PE labeled 2o 
antibody (green channel) and replicate detection of TNF-α at spots B1 and C1 with an APC 
labeled 2o antibody (red channel). (b) Human IL-2 concentration series visualized using a 
fluorescent 2o antibody for detection.  (c) Human IL-2 concentration series developed using Au 
electroless deposition as a visualization and amplification strategy. 
We explored the sensitivity limits of a microfluidics, DEAL-based sandwich 
immunoassay, using a third interleukin, IL-2.  Using a fluorescent readout strategy, the 
assay peaked with a sensitivity limit of around 1 nM on slides printed at saturating 
concentrations of 5 μM of complementary DNA.  Several strategies were employed to 
increase the sensitivity.  First, we reasoned that increasing the loading capacity of the 
glass slide for DNA will increase the density of DEAL conjugates localized and 
therefore, increase the number of capture events possible.  Conventional DNA 
microarrays are printed on primary amine surfaces generated by reacting amine-silane 
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with glass (53).  DNA strands are immobilized through electrostatic interactions between 
the negative charges on the phosphate backbone of DNA and the positive charges from 
the protonated amines at neutral pH conditions.  To increase the loading capacity of the 
slide, we generated poly-lysine surfaces, increasing both the charge density as well as the 
surface area of interaction with DNA.  By adopting these changes, it became possible to 
print complementary DNA at saturating concentrations of 100 μM on the glass slides.  
Correspondingly, the sensitivity of the fluorescent based assays increased to 10 pM 
(Figure 2.8b).  In addition, we chose to employ Au nanoparticle-labeled 2o antibodies, 
followed by electroless metal deposition (54), to further amplify the signal and transform 
a florescence based read out to an optical one.  This is possible since spatial, rather than 
colorimetric multiplexing, is utilized.  Adopting these improvements, the presence of IL-
2 interleukin can be readily detected at a concentration limit less than 10 fM (Figure 
2.8c), representing at least a 1000-fold sensitivity increase over the fluorescence based 
microfluidics immunoassay.  In comparison, this method is 100–1000-fold more sensitive 
than conventional ELISA (55), and 150 times more sensitive than the corresponding 
human IL-2 ELISA data from the manufacturer (56).     
In performing these experiments, the idea of a 1 step immunoassay was revised.  
The sensitivity of the assays was reduced when performing a 1 step immunoassay, 
especially at lower concentrations of antigen.  This is most likely due to competitive 
binding between DEAL conjugates with and without cargo for hybridization unto the 
underlying DNA microarray.  By sequentially exposing the array to DEAL conjugate, 
antigen, and then secondary antibody, the sensitivities were increased.  This is a clear 
trade off between convenience and sensitivity.  It should still be stressed however, that 
40 
 
maximum signal is still reached under microfluidic flowing conditions within 10 minutes 
for each step.  Thus in a fully automated device, a complete microfluidic immunoassay 
with sensitivities down to 10 fM can be obtained in 1 hour (including a 30 minute step for 
Au amplification).  
In addition to the sample size and time-scale benefits that accompany this type of 
microfluidics immunoassay, there are other advantages.  For example, since the entire 
assay is performed in solution prior to read-out, protein denaturation (a concern for 
spotted antibody microarrays) does not reduce binding efficiency.  In addition, any assay 
that involves substrate-supported antibodies, would not have survived microfluidic chip 
assembly (which involved an extended bake at 80oC).  That procedure was designed to 
yield robust PDMS microfluidics channels that could then be disassembled for the optical 
readout step.  Another benefit of performing solution phase assays is that the orientational 
freedom enjoyed by both the antigens and antibodies ensures that the solid support will 
not limit the access of analytes to the binding pocket of the capture agent.  We explore 
this issue in further detail below in the section of cell sorting.  Other improvements, such 
as reducing the DNA spot size (57), and removing spot redundancy are currently being 
investigated to further lower detection limits. 
2.3.5 Multiplexed sorting of immortalized and primary immune cells 
 We extended the DEAL technique for multiplexed cell sorting.  The most 
common method for cell sorting is FACS, which is well-suited for many applications.  
Unfortunately, cells separated by conventional FACS are not immediately available for 
post-sorting analysis of gene and/or protein expression.  In addition, FACS is also limited 
by the number of spectrally distinct fluorophores that can be utilized to label the cell 
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surface markers used for the sorting.  FACS, however, is robust in sorting cells according 
to multiple cell surface markers.  Amongst other alternative cell sorting strategies, the 
traditional panning method, in which cells interact with surface marker-specific 
antibodies printed onto an underlying substrate (58), is particularly relevant. Panning is 
capable of separating multiple cell populations, but has the same limitations as 
conventional spotted protein microarrays, namely that antibodies are not always oriented 
appropriately on a surface, and they can also dry out and lose functionality.  DEAL 
overcomes this limitation, by keeping all reagents in solution. 
We compared DEAL-based cell sorting with panning by evaluating homogeneous 
cell capture (solution phase cell capture) and heterogeneous capture of cells (surface 
confined cell capture).  The homogeneous DEAL method exhibited higher cell capture 
efficiency as shown in Figure 9a,b.  The increase in capture efficiency can be attributed 
to several factors.  In homogeneous cell capture, the DEAL conjugates are allowed to 
properly orient and bind to the cell surface markers in solution.  Cell capture is not driven 
by antibody to cell surface marker interactions, but rather by the increased avidity of the 
multivalent DEAL conjugates for the complementary DNA strands on the microarray 
through cooperative binding, greatly increasing capture efficiency.  Similar trends have 
been reported for nanoparticle, DNA hybridization schemes (59).  With this process, it is 
typical to see a DNA spot entirely occupied by a confluent layer of cells.  With panning 
methods, which are analogous to our (heterogeneous) DEAL defined arrays, the capture 
agents are restricted to adopt a random orientation on the surface.  The activity of the 
antibodies is reduced, simply because of improper orientation for interaction with the cell 
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surface markers, decreasing maximum avidity and cooperation with neighboring 
antibodies. 
 
Figure 2.9  Optimization and use of DEAL for multiplexed cell sorting.  Panels a and b are 
brightfield images showing the efficiency of the homogeneous DEAL cell capture process.  (a) 
DEAL labeled antibodies are first assembled onto a spotted DNA array, followed by introduction 
of the cells.  This heterogeneous process is similar to the traditional panning method of using 
surface bound antibodies to trap specific cells.  (b) A homogeneous assay in which DEAL labeled 
antibodies are combined with the cells, and then the mixture is introduced onto the spotted DNA 
array microchip.  This process is clearly much more efficient. Brightfield and fluorescence 
microscopy images of multiplexed cell sorting experiments where a 1:1 mixture of mRFP-
expressing T cells (red channel) and EGFP-expressing B cells (green channel) is spatially 
stratified onto spots A1 and B1, corresponding to the encoding of α-CD90.2 and α-B220 
antibodies with A1’ and B1’, respectively.  (c) Fluorescence micrograph of multiplexed sorting of 
primary cells harvested from mice. A 1:1 mixture of CD4+ cells from EGFP transgenic mice and 
CD8+ cells from dsRed transgenic mice are separated to spots A1 and C1 by utilizing DEAL 
conjugates α-CD4-A1’ and α-CD8-C1’, respectively.   
 
We also investigated the use of DEAL for multiplexed cell sorting.  Two unique 
DNA strands were conjugated to antibodies raised against the T cell marker CD90.2 
(Thy1.2) and the B cell marker CD45R (B220), respectively.  Multiplexed DEAL-based 
cell sorting was demonstrated by spatially separating a 1:1 mixture of monomeric Red 
fluorescent protein (60) (mRFP)-expressing T cells  (VL-3, murine thymic lymphoma) 
and EGFP-expressing B cells (mouse B cell lymphoma).  This mixture was incubated 
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with uniquely encoded DNA-antibody conjugates against both T and B cell markers and 
introduced to an appropriately spotted microarray. Figure 2.9c shows both brightfield 
and false color fluorescence micrographs demonstrating that the mRFP-expressing T cells 
are enriched at spots A1 and EGFP-expressing B-cells located at B1, consistent with the 
DNA-encoding of the respective antibodies. 
 Primary cells are usually more fragile than established cell lines. This is due to the 
fact that they have to be extracted (usually by enzymatic digestions) from the surrounding 
tissues, a process that can lead to decreased viability. Moreover, the culture process often 
selects for clones characterized by greatly increased viability as well as proliferation 
potential.  A generalized cell sorting technology must therefore also work on primary 
cells with minimal sample manipulation.  To demonstrate the utility of DEAL for primary 
cell sorting, a synthetic mixture of CD4+ and CD8+ T cells was isolated via magnetic 
negative depletion from EGFP- and dsRED- transgenic mice, respectively.  The mixture 
was stratified using α-CD4 and α-CD8 DNA-antibody conjugates. As shown in Figure 
2.9d, the two cell types were separated to different spatial locations according to the 
pendant DNA encoding. 
2.3.6 Single environment detection of specific cDNAs, proteins and cells 
 To highlight the universal diversity of this platform, GFP-expressing B cells were 
tagged with B1’ DNA-encoded antibody conjugates and spatially located onto spots (B1) 
encoded with the complementary oligonucleotide.  Post cell localization, FITC-labeled 
A1’ DNA and a C1’-encoded TNF-α immunosandwich, were combined and introduced 
to the same microarray platform.  The resulting brightfield and fluorescence microscopy 
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images, shown in Figure 2.10, demonstrate the validity of the DEAL platform for 
simultaneously extending across different levels of biological complexity. 
 
Figure 2.10  Microscopy images demonstrating simultaneous cell capture at spot B1 and 
multi-parameter detection of genes and proteins, at spots A1 and C1, respectively. The 
brightfield image shows EGFP-expressing B cells (green channel) located to spots B1, FITC-
labeled (green) cDNA at A1, and an APC-labeled TNF-α sandwich immunoassay (blue) encoded 
to C1. The scale bar corresponds to 300 μm. 
 
2.4 Conclusions 
By utilizing DNA as a universal linkage we have demonstrated a platform capable 
of simultaneous cell sorting, ssDNA and protein detection.  DEAL represents a promising 
approach for the large scale, multi-parameter analysis of biological samples.  We are 
currently applying DEAL towards the separation of highly complex primary cell mixtures 
such as whole mouse spleen and whole mouse thymus extracts.  In addition, 
microfluidics-based DEAL immunoassays arrays are currently being harnessed for the 
analysis of protein biomarker panels from mouse whole-blood.  We are particularly 
interested in integrating DEAL with advanced, on chip tissue handling tasks followed by 
simultaneous quantitation of mRNAs and proteins, because this is where DEAL can 
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potentially assist in pathological analysis of cancerous tissues.  From a more fundamental 
cancer biology perspective, a near-term targeted application is the capture and functional 
evaluation of tumor-specific cytotoxic lymphocytes (28, 61).  Such an application 
requires both rare cell capture, cell activation, and the subsequent detection of secreted 
proteins.  For such problems, DEAL has the potential to eliminate any adverse effects of 
sample dilution and can thus greatly simplify the analysis of the biological system. 
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2.6 Appendix A:  Computational derivation of Orthogonal 
DNA oligomers 
 There are several applications of the computational algorithm developed by Dirks 
et al. (38).  First it can accept a list of sequences (A, B, C, … n) and return with an 
exhaustive file listing the relative interaction strengths between any two DNA sequences.  
This value, reported as n(s*), roughly represents the orthogonality of the two sequences 
that are being compared.  As an example, sequences A1, B1 and C1 (inputs as A, B, and C 
respectively) were analyzed and the results are listed in Appendix 2.6.1.  Here, the 
interaction strength of sequence B with B, representing intra-strand interactions, has the 
lowest n(s*)value of 7.525723, and thus is the most orthogonal pair.  In comparison, 
the interaction strength of An with An (n represents the complement operator) has the 
highest n(s*) value of 16.406083 and thus is the least orthogonal pair.  A good 
measure of the global orthogonality of a set of sequences is determined by the set with 
the lowest Σ n(s*). 
 Besides analysis, a set of sequences can be generated by inputing a set of 
constraints (e.g. sequence length, defined sequences, etc.) and the program will return 
with a set of sequences ranked according to n(s*) adhering to the given constraints.  An 
example of this is given by the input file shown in Appendix 2.6.2, where the input code 
asks for 3 orthogonal sequences (A, B, and C) such that each sequences begins with 
a polyA10 header before a variable 20mer region.  The set of sequences (truncated to 
show only 3 sets of 10 total) with the lowest n(s*) value of 149.225 was taken and 
defined to be A3, B3 and C3, the sequences used in this chapter (Appendix 2.6.3).  This 
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process can be repeated iteratively to increase the number of orthogonal sequences.  
Example input (Appendix 2.6.4) and output (Appendix 2.6.5) is given for the 
computation of a fourth DNA sequence.          
 
2.6.1 Computational analysis of sequence A1, B1, and C1 
Results sorted by n(s*) sum 
 
A_A: 
AAAAAAAAAACGTGACATCATGCATG+AAAAAAAAAACGTGACATCATGCATG 15.893007 
..........................+.......................... <- target 
..................((((((((+..................)))))))) <- predicted 
An_An: 
AAAAAAAAAACATGCATGATGTCACG+AAAAAAAAAACATGCATGATGTCACG 16.406083 
..........................+.......................... <- target 
..........((((((((........+..........))))))))........ <- predicted 
An_Bn: 
AAAAAAAAAACATGCATGATGTCACG+AAAAAAAAAAACTGGTATGCGAATCC 9.679928 
..........................+.......................... <- target 
..........................+.......................... <- predicted 
An_Cn: 
AAAAAAAAAACATGCATGATGTCACG+AAAAAAAAAAATGTGCAATGCGTCCA 11.736368 
..........................+.......................... <- target 
..........................+.......................... <- predicted 
An_B: 
AAAAAAAAAACATGCATGATGTCACG+AAAAAAAAAAGGATTCGCATACCAGT 10.011576 
..........................+.......................... <- target 
...........((((...........+................))))...... <- predicted 
An_C: 
AAAAAAAAAACATGCATGATGTCACG+AAAAAAAAAATGGACGCATTGCACAT 13.267340 
..........................+.......................... <- target 
..........................+.......................... <- predicted 
B_B: 
AAAAAAAAAAGGATTCGCATACCAGT+AAAAAAAAAAGGATTCGCATACCAGT 7.525723 
..........................+.......................... <- target 
..........................+.......................... <- predicted 
Bn_Bn: 
AAAAAAAAAAACTGGTATGCGAATCC+AAAAAAAAAAACTGGTATGCGAATCC 8.707963 
..........................+.......................... <- target 
...................((.....+...................))..... <- predicted 
Bn_Cn: 
AAAAAAAAAAACTGGTATGCGAATCC+AAAAAAAAAAATGTGCAATGCGTCCA 9.372607 
..........................+.......................... <- target 
..........................+.......................... <- predicted 
Bn_A: 
AAAAAAAAAAACTGGTATGCGAATCC+AAAAAAAAAACGTGACATCATGCATG 9.717578 
..........................+.......................... <- target 
................((((......+.....................)))). <- predicted 
Bn_C: 
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AAAAAAAAAAACTGGTATGCGAATCC+AAAAAAAAAATGGACGCATTGCACAT 12.147723 
..........................+.......................... <- target 
................(((((.....+..............)))))....... <- predicted 
C_C: 
AAAAAAAAAATGGACGCATTGCACAT+AAAAAAAAAATGGACGCATTGCACAT 14.639235 
..........................+.......................... <- target 
...............(((.(((....+...............))).))).... <- predicted 
Cn_Cn: 
AAAAAAAAAAATGTGCAATGCGTCCA+AAAAAAAAAAATGTGCAATGCGTCCA 14.117287 
..........................+.......................... <- target 
..............(((.(((.....+..............))).)))..... <- predicted 
Cn_A: 
AAAAAAAAAAATGTGCAATGCGTCCA+AAAAAAAAAACGTGACATCATGCATG 12.522849 
..........................+.......................... <- target 
..........................+.......................... <- predicted 
Cn_B: 
AAAAAAAAAAATGTGCAATGCGTCCA+AAAAAAAAAAGGATTCGCATACCAGT 15.107010 
..........................+.......................... <- target 
.................((((((((.+..........)))..)))))...... <- predicted 
D: 
C 0.000000 
. <- target 
. <- predicted 
Total n(s*) = 180.852 
 
2.6.2 Computing orthogonal sequences A, B, and C constrained by a polyA10 
header: input file 
 
R: 10, 20, 20, 20   %%Defining R to contain 10, or 20 bases 
R1: AAAAAAAAAA  %%Defining the first 10 bases to be polyA10 
 
A_A: 1, 2, 1, 2 %%Sequence A is composed of R1 = polyA10, and R2 
which is variable 20 mer 
..............................+.............................. 
An_An: 1, -2, 1, -2 
..............................+.............................. 
An_Bn: 1, -2, 1, -3 
..............................+.............................. 
An_Cn: 1, -2, 1, -4 
..............................+.............................. 
An_B: 1, 2, 1, 3 
..............................+.............................. 
An_C: 1, 2, 1, 4 
..............................+.............................. 
B_B: 1, 3, 1, 3 
..............................+.............................. 
Bn_Bn: 1, -3, 1, -3 
..............................+.............................. 
Bn_Cn: 1, -3, 1, -4 
..............................+.............................. 
Bn_A: 1, -3, 1, 2 
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..............................+.............................. 
Bn_C: 1, -3, 1, 4 
..............................+.............................. 
C_C: 1, 4, 1, 4 
..............................+.............................. 
Cn_Cn: 1, -4, 1, -4 
..............................+.............................. 
Cn_A: 1, -4, 1, 2 
..............................+.............................. 
Cn_B: 1, -4, 1, 3 
..............................+.............................. 
 
2.6.3 PolyA10 header computational results  
Results sorted by n(s*) sum 
 
A_A: 
AAAAAAAAAACGTGCCTACGGATCATTCTA+AAAAAAAAAACGTGCCTACGGATCATTCTA 14.752380 
..............................+.............................. <- target 
..........(((....)))..........+..........(((....))).......... <- predicted 
An_An: 
AAAAAAAAAATAGAATGATCCGTAGGCACG+AAAAAAAAAATAGAATGATCCGTAGGCACG 12.191140 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
An_Bn: 
AAAAAAAAAATAGAATGATCCGTAGGCACG+AAAAAAAAAATACGAGCTACTAAGTGTCCG 10.821610 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
An_Cn: 
AAAAAAAAAATAGAATGATCCGTAGGCACG+AAAAAAAAAATACCGAGTCAGGACCGTCGC 11.704642 
..............................+.............................. <- target 
...................((...))....+.............................. <- predicted 
An_B: 
AAAAAAAAAATAGAATGATCCGTAGGCACG+AAAAAAAAAACGGACACTTAGTAGCTCGTA 12.387949 
..............................+.............................. <- target 
..................(((((.......+.........)))))................ <- predicted 
An_C: 
AAAAAAAAAATAGAATGATCCGTAGGCACG+AAAAAAAAAAGCGACGGTCCTGACTCGGTA 13.792005 
..............................+.............................. <- target 
...................((((..((...+..........)).))))............. <- predicted 
B_B: 
AAAAAAAAAACGGACACTTAGTAGCTCGTA+AAAAAAAAAACGGACACTTAGTAGCTCGTA 15.189105 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Bn_Bn: 
AAAAAAAAAATACGAGCTACTAAGTGTCCG+AAAAAAAAAATACGAGCTACTAAGTGTCCG 10.362398 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Bn_Cn: 
AAAAAAAAAATACGAGCTACTAAGTGTCCG+AAAAAAAAAATACCGAGTCAGGACCGTCGC 11.009212 
..............................+.............................. <- target 
............((................+........................)).... <- predicted 
Bn_A: 
AAAAAAAAAATACGAGCTACTAAGTGTCCG+AAAAAAAAAACGTGCCTACGGATCATTCTA 11.155809 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
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Bn_C: 
AAAAAAAAAATACGAGCTACTAAGTGTCCG+AAAAAAAAAAGCGACGGTCCTGACTCGGTA 12.599213 
..............................+.............................. <- target 
............((((..............+.......................))))... <- predicted 
C_C: 
AAAAAAAAAAGCGACGGTCCTGACTCGGTA+AAAAAAAAAAGCGACGGTCCTGACTCGGTA 22.259374 
..............................+.............................. <- target 
.........(.(((..(((..((((((.(.+.........).)))..)))..)))))).). <- predicted 
Cn_Cn: 
AAAAAAAAAATACCGAGTCAGGACCGTCGC+AAAAAAAAAATACCGAGTCAGGACCGTCGC 15.521820 
..............................+.............................. <- target 
..................(..(........+..................)..)........ <- predicted 
Cn_A: 
AAAAAAAAAATACCGAGTCAGGACCGTCGC+AAAAAAAAAACGTGCCTACGGATCATTCTA 12.952999 
..............................+.............................. <- target 
.......................((((...+.................))))......... <- predicted 
Cn_B: 
AAAAAAAAAATACCGAGTCAGGACCGTCGC+AAAAAAAAAACGGACACTTAGTAGCTCGTA 13.708535 
..............................+.............................. <- target 
.......................((((...+.........))))................. <- predicted 
Total n(s*) = 200.408 
 
... 
 
A_A: 
AAAAAAAAAAATCAAGTAGCGAATGGACTA+AAAAAAAAAAATCAAGTAGCGAATGGACTA 7.851744 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
An_An: 
AAAAAAAAAATAGTCCATTCGCTACTTGAT+AAAAAAAAAATAGTCCATTCGCTACTTGAT 10.114856 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
An_Bn: 
AAAAAAAAAATAGTCCATTCGCTACTTGAT+AAAAAAAAAATACCGTGAAGCGTCCTAGTA 11.335990 
..............................+.............................. <- target 
...................((((.......+..................))))........ <- predicted 
An_Cn: 
AAAAAAAAAATAGTCCATTCGCTACTTGAT+AAAAAAAAAATAGATACGATGGCTCAGTGC 11.862416 
..............................+.............................. <- target 
...............(..............+....................)......... <- predicted 
An_B: 
AAAAAAAAAATAGTCCATTCGCTACTTGAT+AAAAAAAAAATACTAGGACGCTTCACGGTA 11.058647 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
An_C: 
AAAAAAAAAATAGTCCATTCGCTACTTGAT+AAAAAAAAAAGCACTGAGCCATCGTATCTA 10.700609 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
B_B: 
AAAAAAAAAATACTAGGACGCTTCACGGTA+AAAAAAAAAATACTAGGACGCTTCACGGTA 14.394146 
..............................+.............................. <- target 
............((((..((.....))...+............))))..((.....))... <- predicted 
Bn_Bn: 
AAAAAAAAAATACCGTGAAGCGTCCTAGTA+AAAAAAAAAATACCGTGAAGCGTCCTAGTA 13.083925 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Bn_Cn: 
AAAAAAAAAATACCGTGAAGCGTCCTAGTA+AAAAAAAAAATAGATACGATGGCTCAGTGC 12.305284 
..............................+.............................. <- target 
....................(((.......+...............)))....(.....). <- predicted 
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Bn_A: 
AAAAAAAAAATACCGTGAAGCGTCCTAGTA+AAAAAAAAAAATCAAGTAGCGAATGGACTA 9.982085 
..............................+.............................. <- target 
.....................(........+...........................).. <- predicted 
Bn_C: 
AAAAAAAAAATACCGTGAAGCGTCCTAGTA+AAAAAAAAAAGCACTGAGCCATCGTATCTA 10.427249 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
C_C: 
AAAAAAAAAAGCACTGAGCCATCGTATCTA+AAAAAAAAAAGCACTGAGCCATCGTATCTA 8.990198 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Cn_Cn: 
AAAAAAAAAATAGATACGATGGCTCAGTGC+AAAAAAAAAATAGATACGATGGCTCAGTGC 9.885630 
..............................+.............................. <- target 
................((....(.....).+................))....(.....). <- predicted 
Cn_A: 
AAAAAAAAAATAGATACGATGGCTCAGTGC+AAAAAAAAAAATCAAGTAGCGAATGGACTA 9.740523 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Cn_B: 
AAAAAAAAAATAGATACGATGGCTCAGTGC+AAAAAAAAAATACTAGGACGCTTCACGGTA 10.394821 
..............................+.............................. <- target 
..............................+..................((.....))... <- predicted 
Total n(s*) = 162.128 
 
... 
 
A_A: 
AAAAAAAAAAATCCTGGAGCTAAGTCCGTA+AAAAAAAAAAATCCTGGAGCTAAGTCCGTA 11.081137 
..............................+.............................. <- target 
............((.((.............+............)).))............. <- predicted 
An_An: 
AAAAAAAAAATACGGACTTAGCTCCAGGAT+AAAAAAAAAATACGGACTTAGCTCCAGGAT 11.417329 
..............................+.............................. <- target 
....................((........+....................))........ <- predicted 
An_Bn: 
AAAAAAAAAATACGGACTTAGCTCCAGGAT+AAAAAAAAAATAGGCATGATTCAATGAGGC 9.031869 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
An_Cn: 
AAAAAAAAAATACGGACTTAGCTCCAGGAT+AAAAAAAAAATAGCGATAGTAGACGAGTGC 9.887457 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
An_B: 
AAAAAAAAAATACGGACTTAGCTCCAGGAT+AAAAAAAAAAGCCTCATTGAATCATGCCTA 9.893760 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
An_C: 
AAAAAAAAAATACGGACTTAGCTCCAGGAT+AAAAAAAAAAGCACTCGTCTACTATCGCTA 9.416199 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
B_B: 
AAAAAAAAAAGCCTCATTGAATCATGCCTA+AAAAAAAAAAGCCTCATTGAATCATGCCTA 10.372686 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Bn_Bn: 
AAAAAAAAAATAGGCATGATTCAATGAGGC+AAAAAAAAAATAGGCATGATTCAATGAGGC 11.143822 
..............................+.............................. <- target 
...............((.............+...............))............. <- predicted 
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Bn_Cn: 
AAAAAAAAAATAGGCATGATTCAATGAGGC+AAAAAAAAAATAGCGATAGTAGACGAGTGC 9.725931 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Bn_A: 
AAAAAAAAAATAGGCATGATTCAATGAGGC+AAAAAAAAAAATCCTGGAGCTAAGTCCGTA 9.849003 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Bn_C: 
AAAAAAAAAATAGGCATGATTCAATGAGGC+AAAAAAAAAAGCACTCGTCTACTATCGCTA 10.070369 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
C_C: 
AAAAAAAAAAGCACTCGTCTACTATCGCTA+AAAAAAAAAAGCACTCGTCTACTATCGCTA 8.656702 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Cn_Cn: 
AAAAAAAAAATAGCGATAGTAGACGAGTGC+AAAAAAAAAATAGCGATAGTAGACGAGTGC 9.905828 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Cn_A: 
AAAAAAAAAATAGCGATAGTAGACGAGTGC+AAAAAAAAAAATCCTGGAGCTAAGTCCGTA 9.691171 
..............................+.............................. <- target 
......................(((.....+..........................))). <- predicted 
Cn_B: 
AAAAAAAAAATAGCGATAGTAGACGAGTGC+AAAAAAAAAAGCCTCATTGAATCATGCCTA 9.081401 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Total n(s*) = 149.225 
 
2.6.4 Computing a fourth sequence: input code 
>Test #6 
R: 10, 20, 20, 20, 20   
R1: AAAAAAAAAA 
R2: ATCCTGGAGCTAAGTCCGTA 
R3: GCCTCATTGAATCATGCCTA 
R4: GCACTCGTCTACTATCGCTA 
 
D_D: 1, 5, 1, 5 
..............................+.............................. 
Dn_A: 1, -5, 1, 2 
..............................+.............................. 
Dn_B: 1, -5, 1, 3 
..............................+.............................. 
Dn_C: 1, -5, 1, 4 
..............................+.............................. 
Dn_An: 1, -5, 1, -2 
..............................+.............................. 
Dn_Bn: 1, -5, 1, -3 
..............................+.............................. 
Dn_Cn: 1, -5, 1, -4 
..............................+.............................. 
Dn_Dn: 1, -5, 1, -5 
..............................+.............................. 
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2.6.5 Results of fourth strand computation  
D_D: 
AAAAAAAAAAATGGTCGAGATGTCAGAGTA+AAAAAAAAAAATGGTCGAGATGTCAGAGTA 10.604201 
..............................+.............................. <- target 
...............((.............+...............))............. <- predicted 
Dn_A: 
AAAAAAAAAATACTCTGACATCTCGACCAT+AAAAAAAAAAATCCTGGAGCTAAGTCCGTA 7.984174 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Dn_B: 
AAAAAAAAAATACTCTGACATCTCGACCAT+AAAAAAAAAAGCCTCATTGAATCATGCCTA 6.890737 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Dn_C: 
AAAAAAAAAATACTCTGACATCTCGACCAT+AAAAAAAAAAGCACTCGTCTACTATCGCTA 6.684232 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Dn_An: 
AAAAAAAAAATACTCTGACATCTCGACCAT+AAAAAAAAAATACGGACTTAGCTCCAGGAT 7.998166 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Dn_Bn: 
AAAAAAAAAATACTCTGACATCTCGACCAT+AAAAAAAAAATAGGCATGATTCAATGAGGC 9.261694 
..............................+.............................. <- target 
..............................+.............................. <- predicted 
Dn_Cn: 
AAAAAAAAAATACTCTGACATCTCGACCAT+AAAAAAAAAATAGCGATAGTAGACGAGTGC 11.865802 
..............................+.............................. <- target 
.....................((((.....+.......................))))... <- predicted 
Dn_Dn: 
AAAAAAAAAATACTCTGACATCTCGACCAT+AAAAAAAAAATACTCTGACATCTCGACCAT 6.770436 
..............................+.............................. <- target 
.......................((.....+.......................))..... <- predicted 
Total n(s*) = 68.059 
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2.7 Appendix B:  FPLC of DEAL conjugates.   
 
 
*0.5 mL/min isocratic flow of PBS 
Figure 2.11  Fast protein liquid chromatography of DEAL conjugates.  A typical successful 
conjugation reaction will yield three distinct peaks, corresponding to the DEAL conjugates, 
excess unreacted ssDNA, and excess small molecules.   
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Chapter 3 
Modular Nucleic Acid Assembled p/MHC 
Microarrays for Multiplexed Sorting of Antigen-
Specific T Cells 
 
 
 
2.1 Introduction 
T cells constitute an important part of the acquired immune system. They 
recognize a diversity of antigens through the highly variable, hetero-dimeric T cell 
receptor protein (TCR), with approximately 107 different antigen specificities (1).  The 
initiation of the T cell immune response is triggered by the engagement of the TCR with 
processed antigenic peptides (e.g. from a bacterial pathogen) that are bound to Major 
Histocompatibility Complex (p/MHC) molecules presented on the surface of antigen 
presenting cells (APCs), leading to downstream T cell proliferation and maturation into 
effecter populations.  After pathogen clearance, a subset of the activated T cells transition 
into memory cells, providing the immune system with the capacity for rapid response 
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towards previously encountered pathogens.  As a consequence, an individual’s collection 
of T cells and their antigen specificities, collectively called the T cell repertoire, is an 
evolving, extensive repository of cellular immune responses against self and foreign 
antigens.  It is of fundamental and therapeutic importance to detect and survey these T 
cell populations.  
The development of soluble p/MHC tetramers for labeling antigen-specific T cells 
has enabled the direct phenotypic analysis of antigen-specific T cell populations with 
flow cytometry (2).  Conventionally, p/MHC tetramers are prepared by mixing 
enzymatically biotinylated p/MHC molecules with preparations of streptavidin (SA)-
fluorophore conjugates.  While p/MHC monomers have low affinities (2, 3), their 
tetramer counterparts exhibit much higher avidity, permitting T cell detection via flow 
cytometry to become a standard assay.  However, because p/MHC tetramer-stained T cell 
populations are encoded optically (i.e. one unique fluorophore required per p/MHC 
specificity), the number of antigen-specificities that can be interrogated simultaneously 
within a population is limited by spectral overlap.  In addition, serial flow cytometry 
detection of distinct antigen-specific T cells is generally restricted by sample size.  
Efforts to increase the degree of multiplexing generally revolve around polychromatic 
flow cytometry utilizing quantum dots (4, 5).  However, cost, sample preparation time, 
and color compensation complexity also increase correspondingly.     
As an alternative to flow cytometry, several groups have reported microarray-
based T cell detection schemes, in which collections of p/MHC complexes are printed on 
a supporting substrate (6–9).  A population of cells is applied directly to the p/MHC array 
where target antigen-specific T cells bind to regions spotted with the cognate p/MHC and 
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are detected optically. Analogous to DNA and protein microarrays, the readout of such 
assays is dependent on location rather than distinct fluorescent signals, thus potentially 
increasing the degree of multiplexing.   
 A factor that needs to be addressed before p/MHC arrays are used for broader 
studies and applications concerns the reproducibility and robustness of p/MHC arrays 
produced by spotting onto treated and/or derivatized surfaces.  Ideally p/MHC complexes 
should be immobilized such that their functional conformations are preserved.  
Analogous protein arrays produced via antibody adsorption to unmodified and 
derivatized surfaces can suffer from surface induced effects including protein 
denaturation and protein adsorption in inactive orientations (10–12).  To circumvent such 
problems, customized surfaces and relatively mild chemistries for protein immobilization 
have been developed (13–18).  However, often the surface that meets the demands of the 
application requires a high level of technical expertise and/or is limited in accessibility 
(19).   
We report here on the method of Nucleic Acid Cell Sorting (NACS), which is 
based upon the design and application of nucleic acid assembled p/MHC tetramer arrays 
for multiplexed sorting of antigen-specific T cells.  For NACS, p/MHC tetramers of 
distinct specificities are conjugated to unique sequences of ssDNA in a site-specific 
fashion.  A collection of ssDNA-tagged p/MHC complexes is then self-assembled by 
DNA hybridization onto a glass slide printed with the complementary DNA sequences.  
Fully assembled p/MHC tetramer arrays are used to sort mixed populations of antigen-
specific T cells (Figure 3.1).  This strategy of using DNA pendants as molecular linkages 
(20-25) is simple and highly modular.  Most importantly, T cell array binding is 
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optimized by utilizing cysteine-engineered streptavidin (SAC) for ssDNA-p/MHC 
tetramer production, resulting in NACS p/MHC arrays that outperform conventional 
spotted arrays assessed by performance criteria such as reproducibility and homogeneity.  
The versatility of using DNA tags is also exploited to enable selective detachment of T 
cells with restriction endonucleases.  Demonstrative experiments regarding NACS 
sensitivity, multiplexing and limit of detection are performed with cell lines and finally 
with T cells isolated from cancer patients.    
   
 
Figure 3.1  Self-assembled ssDNA-p/MHC tetramer arrays for multiplexed sorting of 
antigen-specific cells  ssDNA-tagged p/MHC tetramers are produced by coupling ssDNA site-
specifically to SAC prior to exposure to molar excess of biotinylated p/MHC monomers.  p/MHC 
tetramer arrays are formed by pooling ssDNA-p/MHC tetramers of select specificity and 
hybridization to a complementary printed ssDNA microarray.  T cells expressing the cognate 
TCR are detected by binding to the surface confined tetramer. 
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3.2 Experimental Methods  
3.2.1 Microarray Fabrication    
All DNA strands were purchased from IDT with HPLC purification.  DNA 
microarrays were printed by the microarray facility at the Institute for Systems Biology 
(ISB—Seattle, WA) on amine-coated glass slides (GAPS II, Corning) in identical 
triplicate 12x12 arrays containing alternative rows of A, B and C spots, or AEcoRI and 
BBamHI with a SMPXB15 pin (Arrayit).  Sequences for all strands can be found at Table 
3.1. 
Table 3.1  Orthogonal DNA sequences for spatial encoding of p/MHC tetramers  
 
Name    Sequence*
 
 
A            5’ - AAA AAA AAA AAA AAT CCT GGA GCT AAG TCC GTA AAA AAA AAA AAT CCT 
GGA GCT AAG TCC GTA AAA AAA AAA AAA A 
A’           5' - NH2- AAA AAA AAA ATA CGG ACT TAG CTC CAG GAT 
B            5' - AAA AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA AAA AAA AAA AGC CTC 
ATT GAA TCA TGC CTA AAA AAA AAA AAA A 
B’           5' - NH2- AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC 
C            5' - AAA AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA AAA AAA AAA AGC ACT 
CGT CTA CTA TCG CTA AAA AAA AAA AAA A 
C’           5' - NH2- AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC 
AEcoRI     5’ - AAA AAA AAA AAA GAG CTA AGT CCG TAG AAT TCA AAA AAA AAA GAG CTA 
AGT CCG TAG AAT TCA AAA AAA AAA AAA 
AEcoRI’    5’ - NH2 – AAA AAA AAA AGA ATT CTA CGG ACT TAG CTC CAG GAT 
BBamHI    5’ - AAA AAA AAA AAA TTG AAT CAT GCC TAG GAT CCA AAA AAA AAA TTG        
AAT CAT GCC TAG GAT CCA AAA AAA AAA AAA 
BBamHI’   5’- NH2 – AAA AAA AAA AGG ATC CTA GGC ATG ATT CAA TGA GGC 
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*  All sequences to be conjugated to SAC (A’, B’, C’, AEcoRI’, and BBamHI’) were designed with a 
polyA linker followed by a 20mer hybridization region.  The 5’ amine is required for the 
attachment of the hetero-bifunctional maleimide derivative MHPH.  Sequences printed on glass 
substrates (A, B, C, AEcoRI, and BBamHI) were designed with two hybridization regions separated 
by polyAs.  This was designed to facilitate electrostatic adsorption to amine glass substrates.   
 
 
3.2.2 Production of ssDNA-SAC conjugates 
The pET-3a plasmid containing the SAC gene was a kind gift from Takeshi Sano 
(Harvard Medical School).  The expression of SAC was performed according to 
previously published protocols (26).  Briefly, transformed BL21(DE3)-pLysE cells were 
grown at 37oC with shaking in LB medium and selection antibiotics ampicilin and 
chlorophenicol.  The cells were induced at OD600 = 0.6 with IPTG and kept spinning for 
another 4 hours.  The culture was then centrifuged at 1600g for 10 min and lysed with 
lysis buffer (2 mM EDTA, 30 mM Tris-HCl, 0.1% Triton X-100, pH 8.0).  The insoluble 
inclusion bodies were then separated from the lysate by centrifugation at 39,000g for 15 
min and dissolved in 6 M guanidine-HCl, pH 1.5 to the original culture volume.   The 
SAC lysate was then refolded by dialysis in 0.2 M Sodium acetate, 10 mM β-
mercaptoethanol (β-ME) pH 6.0 overnight before dialyzed against 50mM Sodium 
bicarbonate, 500 mM NaCl, 10 mM β-ME pH 11 in preparation for column purification.  
Refolded volumes of SAC were mixed 1:1 with binding buffer (50 mM Sodium 
bicarbonate, 500 mM NaCl, 10mM β-ME, pH 11).  A gravity column packed with 1.5 ml 
of iminobiotin agarose resin (Pierce) was washed with 10 ml of binding buffer.  The 
refolded mixture was then applied to the column and the eluted fractions were collected 
and reapplied to the column again, to maximize SAC recovery.  After washing the 
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column with 20 ml binding buffer, SAC was eluted with pH 4 elution buffer (50 mM 
Sodium acetate, 10mM β-ME).  Fractions containing SAC, as monitored by OD280, were 
collected, buffer exchanged to PBS containing 10 mM β-ME, and concentrated to 1 
mg/ml final concentration using 10K mwco filters (Millipore).  Immediately prior to 
conjugation, stock SAC was buffer exchanged to PBS containing 5mM Tris(2-
Carboxyethyl) phosphine Hydrochloride (TCEP) using zeba desalting columns (Pierce).  
MHPH (3-N-Maleimido-6-hydraziniumpyridine hydrochloride, Solulink) in DMF was 
added to SAC at a molar excess of 300:1.  In parallel, SFB in DMF (succinimidyl 4-
formylbenzoate, Solulink) was added in a 40:1 molar excess to 5’aminated oligos.  The 
mixtures were reacted at room temperature (RT) for 3–4 hours before buffer exchanged 
to citrate (50mM sodium citrate, 150 mM NaCl, pH 6.0) using zeba columns.  The SFB-
labled oligos were combined in a 20:1 molar excess with the derivatized SAC and 
incubated overnight at RT.  Unreacted oligos were removed using a Pharmacia Superdex 
200 gel filtration column at 0.5 ml/min isocratic flow of PBS.  Fractions containing the 
SAC-oligo conjugates were concentrated using 10K mwco concentration filters 
(Millipore).   
3.2.3 Preparation of T cells 
The cDNA from the alpha and beta chains of a TCR specific for tyrosinase368-
376 was a kind gift from Michael I. Nishimura (Medical University of South Carolina, 
Charleston, SC).  The alpha and beta chains were cloned into a lentiviral vector where 
both transgenes were linked by a 2A self-cleaving sequence as described (27).  
Concentrated supernatant from this lentiviral vector was used to infect Jurkat cells to 
generate Jurkatα-Tyro cells.  The MSGV1-F5AfT2AB retroviral vector expressing the F5 
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MART-1 TCR was a kind gift from Steven A. Rosenberg and Richard Morgan (Surgery 
Branch, National Cancer Institute Bethesda, MD).  The MSGV1-F5AfT2AB retroviral 
supernatant was used to infect Jurkat cells to generate the Jurkatα-MART-1 cell line.  The 
Jurkatα-NY-ESO-1 cell line was a generous gift from Robert Prins (UCLA).  To generate 
primary human T cell cultures expressing the F5 MART-1 TCR, PBMCs obtained from 
leukapheresis were activated for 48 hours with 50 ng/ml of OKT3 (muromonab anti-
human CD3 antibody, Ortho-Biotech, Bridgewater, NJ) and 300 U/ml of IL-2 
(adesleukin, Novartis, Emeryville, CA). MSGV1-F5AfT2AB retrovirus supernatant was 
applied to retronectin-coated wells (Takara Bio Inc., Japan). Then activated PBMC in 
RPMI plus 5% human AB serum supplemented by 300 IU of IL-2 were added to these 
wells and incubated at 37oC overnight at 5% CO2. On the following day, PBMC are 
transferred to a second set of pre-coated retronectin retroviral vector tissue culture plates 
and incubated at 37oC overnight at 5% CO2. Cells were subsequently washed and re-
suspended in culture media described above. Frozen leukapheresis fractions from patients 
NRA11, NRA 13 (UCLA IRB#03-12-023 ) and F5-1 (UCLA IRB #08-02-020-02A) were 
thawed and incubated overnight in RPMI supplemented with 10% human AB serum and 
1% penicillin, streptomycin, and amphotericin (Omega Scientific).  F5-1 cells were used 
immediately following incubation.  NRA11 and NRA13 samples were CD8+ enriched 
(anti-CD8 microbeads, Miltenyi Biotech) using an AutoMACS machine according to the 
manufacturer’s instructions.  Following separation, the cells were kept at in RPMI-
humanAB media containing 30 U IL2/mL.         
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3.2.4 T Cell Sorting Methods  
The HLA-A*0201 restricted MHC class I monomers loaded with tyrosinase369-377 
(YMDGTMSQV), MART-126-35 (ELAGIGILTV)  and NY-ESO-1157-165 
(SLLMWITQC) were produced in house according to previous published protocols (28).  
A2.1-restricted EBV BMLF1259-267 (GLCTLVAML), CMV pp65495-503 (NLVPMVATV), 
murine H-2Kb/-OVA257-264 (SIINFEKL), and murine H-2Db/-gp10025-33 
(KVPRNQDWL) as well as all fluorescent HLA-A*0201 tetramers were purchased from 
Beckman Coulter.  Lipophilic cell membrane staining dyes DiO, DiD, and DiL were 
purchased from Invitrogen.      
Prior to experiments, microarray slides were blocked to prevent non-specific cell 
binding with 1 mg/ml PEG-NHS ester (Sunbio) in PBS for 2 hours at RT.  Four-fold 
molar excess of p/MHC monomers were combined with ssDNA-SAC at 37oC for 20 min.  
ssDNA-p/MHC tetramers were hybridized to DNA arrays for 1 hour at 37oC in 200 μl 
media and rinsed with 3% FBS in PBS. T cells (106 /100 μl media) were incubated on the 
array at 37oC for 30 min.  The arrays were rinsed with 3% FBS in PBS and cell capture 
visualized via brightfield (Nikon Eclipse TE2000) and/or confocal microscropy (Nikon 
E800).  Post T cell capture p/MHC tetramer staining was done by incubating the array 
with 200 μl of media containing fluorescent p/MHC tetramer along with fluorescent 
cDNA (Cy5-A’ and/or Cy3-B’).  The arrays were rinsed with 3% FBS in PBS prior to 
imaging.  For selective T cell release experiments, three identical arrays were used to 
immobilize cells.  Treatment with EcoRI, BamHI, or DNase was in RPMI media for 1–2 
hours at 37oC.  DNase was purchased from Sigma, all other enzymes from NEbiolabs.     
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For p/MHC comparative studies, SuperEpoxy and SuperProtein (representing 
covalent and hydrophobic surfaces respectively) were purchased from Arrayit 
(Sunnyvale, CA).  Amine GAPS II slides (electrostatic) were purchased from Corning.  
Polycarboxylate hydrogel (hydrophilic) slides were purchased from XanTec (Germany).  
Fluorescent MART-1 tetramers were printed according to manufacturer’s instructions for 
each slide.  Cell sorting images were quantified with ImageJ (NIH) and fitted to the Hill 
Function (NACS n=2, R2=0.95, Covalent n=2.1, R2 =0.97) with Origin (OriginLab, 
MA).  
3.3 Results and Discussion  
3.3.1 Rational design of ssDNA-encoded p/MHC tetramers   
The standard scaffold most frequently used to assemble p/MHC monomers into 
tetramers is SA-phycobiliprotein (using the protein fluorophores phycoerythrin (PE) or 
allophycocyanain (APC)) conjugates.  Because SA-phycobiliprotein conjugates are 
produced via chemical cross-linking, most functional groups are exhausted and/or 
modified, prohibiting the conjugation of ssDNA.  In addition, the attachment of 
molecular fluorophores to native SA reduces the binding capacity for biotin, an effect 
attributed to the modification of lysine121 that occurs with amide coupling strategies.  
This residue is in close proximity to the ligand binding pockets (29, 30).  To circumvent 
this, Altman and co-workers (29) employed a recombinant mutant of SA for fluorescent 
p/MHC tetramer preparations.  This variant incorporates a cysteine residue at the 
carboxy-terminus (31), a site removed from the biotin binding pocket.  The conjugation 
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of cysteine-reactive maleimide derivatives is restricted to the C-terminus because 
cysteine residues are absent in native SA.   
We expressed SAC, coupled the protein with 5’-maleimide ssDNA, and verified 
the formation of conjugates with mobility shift assays (Figure 3.2).  In parallel, ssDNA 
was coupled to native SA for direct comparison.  To test biotin binding capacity, SAC-
oligo conjugates were probed with 2-(4'-Hydroxyazobenzene) benzoic acid (HABA) 
(32), a molecular mimic of biotin with distinct optical density coefficients dependent on 
whether biotin is bound to SA or not.  A biotin:SA molar ratio of association significantly 
below 4 in the assay would indicate a reduction in biotin binding capacity.  Conjugates 
derived from native SA were greater than one full unit below the expected value (2.86 
versus 4.0), while conjugates formed with SAC maintained near optimal (3.7) binding 
capacity (Figure 3.2C).  These conjugates were then tested across 4 different monoclonal 
T cell populations (2 human TCR-transduced cell lines and 2 murine TCR-transgenic 
splenocyte cell suspensions).  ssDNA-tagged SAC constructs had markedly higher cell 
capture efficiencies (Figure 3.3B) when compared with p/MHC tetramers prepared with 
native SA (Figure 3.3A).  All subsequent NACS tetramers were prepared with the SAC 
variant. 
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Figure 3.2  An engineered variant of streptavidin expressing C-terminal cysteine residues 
has superior biotin binding capacity compared to native streptavidin post conjugation with 
ssDNA.  (A)  The various stages of SAC expression, refolding, and purification were analyzed on 
a denaturing PAGE gel.  The molecular weight of a SAC monomer is ~12kDa. (B) A gel mobility 
shift assay to verify the formation of ssDNA-SAC conjugates.  Individual bands representing 
SAC-oligo conjugates differing by one DNA strand can be resolved.  Lower order SAC-oligo 
conjugates (1–2 oligos per protein) run “lighter” when compared to unmodified SAC because of 
the difference in charge/mass density of nucleic acids.  Higher order SAC-oligo conjugates 
corresponding to 3–4 DNA strands per SA were favored. (C) The molecule 2-(4'-
Hydroxyazobenzene) benzoic acid (HABA) was used to determine the molar ratio of association 
of biotin to SA.  Native SA-oligo conjugates bound ~2.9 moles of biotin per mole of SA, a 
significant decline when compared to the 4:1 ratio of unmodified SAC.  SAC-oligo conjugates 
maintained near optimum binding capacity (3.7:1). 
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Figure 3.3  T cell capture efficiency is optimal when utilizing ssDNA-SAC conjugates to 
generate NACS p/MHC tetramers (A) ssDNA-p/MHC constructs derived from native SA were 
used to sort 4 different human/murine transgenic T cell populations.  The T cell capture 
efficiencies were highly varied amongst the four T cell populations.  (B) ssDNA-p/MHC 
tetramers derived from ssDNA-SAC conjugates were used to sort the four T cell populations.  
The resulting cell capture efficiencies were markedly improved over native SA-oligo conjugates, 
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demonstrating that SAC is necessary for the production of high affinity ssDNA-p/MHC 
tetramers. 
 
 
3.3.2 Performance of p/MHC arrays produced via DNA immobilization and direct 
spotting 
We directly compared the performance of NACS with conventional direct 
spotting strategies on various model substrates.  The substrates were selected to represent 
the spectrum of surface chemistries typically used to immobilize proteins (covalent, 
electrostatic, hydrophobic, and hydrophilic adsorption).  Serial dilutions of a fluorescent 
p/MHC tetramer, MART-1, were spotted on the substrates according to manufacturer’s 
instructions.  Jurkatα-MART-1 T cells (the human T leukemia cell line Jurkat transduced 
with the F5 MART-1 TCR (33) specific for MART-1) were applied to the array and 
representative images collected (Figure 3.4A) and quantified (Figure 3.4B).  We 
observed little to no T cell capture (electrostatic, hydrophilic) or significant noise 
(hydrophobic) on the majority of the surfaces investigated compared to NACS arrays 
immobilized with identical concentrations of p/MHC tetramers.  T cell binding was 
observed on one surface (covalent) but cell capture was highly variable as evidenced by 
both intra-spot and inter-spot heterogeneity and cross experimental variation (Figure 
3.5).  Moreover, to achieve equivalent T cell capture densities, NACS p/MHC arrays 
required >5 times less material than covalent immobilization. (p/MHC monomer at half 
max ≡ K1/2 = 1.1 ng for NACS and 5.7 ng for covalent immobilization).   
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Figure 3.4  Comparison of NACS versus spotted p/MHC arrays (A) Brightfield and 
fluorescent images of Jurkatα-MART-1 T cells captured on various model substrates. (B) 
Quantification of T cell capture efficiencies (hydrophobic surface was excluded because 
signal:noise ≤ 1).  Each data point was derived from three representative spots. 
The performance and reproducibility of NACS p/MHC arrays is markedly 
improved and represents an integral step towards expanding array-based T cell detection 
schemes for broader applications.  This likely has a few causes.  First, surface-tethered 
ssDNA-p/MHC tetramers may enjoy greater orientational freedom at the surface/solution 
interface compared with adsorbed proteins which are required to conform to the surface.  
This effect may increase the density of functional protein and consequently reduce the 
amount of material required for array production.  Second, the hydration state of the 
environment during the production and subsequent storage of protein arrays is an 
important factor for array reproducibility (10, 13, 18).  This effect is minimized with 
NACS because DNA chips can be printed and stored dry for extended periods of time 
and ssDNA-tagged p/MHC tetramer arrays are self-assembled in solution immediately 
prior to an experiment.       
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Figure 3.5  Comparison of the performance of p/MHC arrays produced by NACs and by 
spotting The consistency and robustness of T cell immobilization with NACS is evident when 
compared directly with spotted arrays, which suffers from significant levels of inter-spot, intra-
spot, and inter-experimental heterogeneity.  Each row represents a separate experiment performed 
on a different slide. 
 
3.3.3 NACS specificity and limit of detection  
To evaluate the specificity of p/MHC array assembly and T cell sorting, a ssDNA-
p/MHC tetramer, tyrosinase, with pendant DNA sequence A’ was hybridized to a DNA 
microarray printed with the complementary strand (A) along with two additional distinct 
sequences (designated B and C).  A homogeneous population of Jurkatα-Tyr cells (Jurkat 
cells transduced with a TCR specific for tyrosinase) (34) was then applied to the array.  
Jurkatα-Tyr T cells localized to the complementary spots (A) containing the hybridized 
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cognate p/MHC but not to spots printed with the non-complementary sequences B and C 
(Figure 3.6A).  The mean binding capacity calculated from three spots (~600 μm) was 
~1486 ± 62 Jurkatα-Tyr T cells.  
 
Figure 3.6  Mulitplexed nucleic acid cell sorting of antigen-specific T cells (A) Tyrosinase 
p/MHC tetramer conjugated to ssDNA sequence A’ was hybridized to an array printed with DNA 
complement strand A and non-complement strands B and C (dashed circles).  Jurkatα-Tyr cells 
were localized to spot A only. (B) A 1:1:1 mixture of Jurkatα-MART-1 (red), Jurkatα-Tyr (green) and 
Jurkatα-NY-ESO-1 cells was selectively sorted on an array hybridized with MART-1, tyrosinase, and 
NY-ESO-1 p/MHC ssDNA-tetramers (top left).  The remaining three panels are representative 
images of spots A, B and C.   
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To illustrate the multiplexing capability of NACS, MART-1, tyrosinase, and NY-
ESO-1 ssDNA-p/MHC tetramers encoded to DNA sequences A,  B and C respectively 
were combined and assembled simultaneously to a three element DNA microarray 
(strands A, B, and C).  A 1:1:1 mixed population of Jurkatα-MART-1, Jurkatα-Tyr and 
Jurkatα-NY-ESO-1 (Jurkat human T cells transduced with the TCR (35) specific for NY-
ESO-1) cells prestained with lipophilic dyes (red, green and blue respectively) was 
applied to the array and localized into alternating columns (Figure 3.6B).  Minimal 
cross-reactivity was observed.  The average density of spots was about a factor of three 
less than homogeneous sorting (440 ± 28 T cells/spot).   
To determine the limit of detection, target populations of Jurkatα-Tyr cells were 
spiked in at 10%, 1% and 0.1% into wild type (w.t.) Jurkat cells and sorted (Figure 3.7).  
The T cell capture density per spot per species for each mixture was enumerated and 
averaged (right panel).  The number of non-specific w.t. Jurkat cells that adhered to the 
array was constant throughout all dilutions while the number of Jurkatα-Tyr T cells 
captured per spot decreased linearly in relation to the fractional composition of Jurkatα-Tyr 
cells with a detection limit that was ~ 1 in 1000 cells—a limit that corresponds well to the 
total number of cells that can be captured per spot.  Thus, the sensitivity of this approach 
is strictly a geometric constraint since antigen-specific T cells that settle on inert areas 
cannot sample and bind to their cognate p/MHC tetramer.  The sensitivity can be 
improved by increasing the size of the capture region (i.e. increase spot diameter and/or 
incorporate spot redundancy) or by reducing inert regions (i.e. increase printing density). 
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Figure 3.7  NACS limit of detection (A) Jurkatα-Tyr cells (red) were serially diluted in wild type 
(WT) Jurkat cells (green) at frequencies 50%, 10%, 1% and 0.1% and detected by NACS. (B) 
The average number of Jurkatα-Tyr cells and WT Jurkat cells plotted in a histogram. 
It should be noted, however, that the sensitivity of this approach cannot be 
increased without limiting scalability.  Since spot diameters are required to be sufficiently 
large to detect a population at low frequency, this sets an upper bound on the number of 
distinct spots that can be patterned on a substrate.  In the current instance, 600 μm spots 
are printed in 12 by 12 grids (~1 in2), enabling the potential identification of 144 distinct 
antigen-specificities ≥ 0.1% from 106 T cells (106 cells is typically required to cover a 1 
in2 region).  In order to detect target populations below 0.1% without decreasing 
multiplexing, p/MHC-specific enrichment strategies (e.g. magnetic bead-based schemes 
(36)) can be implemented prior to cell sorting.  Lastly, the recovery of this technique—
defined as the total number of antigen-specific T cells captured as a fraction of the 
number of T cells applied to the array—is low relative to other sorting technologies like 
FACS and bead-based schemes.  Typical T cell recovery for NACS is ≤ 20% (37).  In 
comparison, fluorescent-based sorting techniques like FACS have high recoveries, since 
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each stained T cell can be identified individually by the cytometer and sorted from the 
null population.  The recovery (as well as sensitivity) of NACS will likely be improved 
by circulating T cells over the p/MHC array with agitation or with integrated microfluidic 
devices to allow T cells to sample the entire array.    
3.3.4 Selective Release of Immobilized T cells with Restriction Endonucleases 
Antigen-specific T cells immobilized onto glass are immediately available for 
secondary assays, since many such as immunohistochemistry (IHC), fluorescent in situ 
hybrization (FISH) and cytokine secretion assays (6, 8) are traditionally performed or are 
compatible with cells localized to a substrate.  However, several other relevant assays, 
such as those designed to assess T cell phenotype or functional status like 
genomic/mRNA analysis or simply further culture for phenotypic enrichment would 
require a method for releasing the captured cells.  Any release scheme should ideally be 
selective for given cell types.  For NACS, we explored whether the DNA tethers could be 
selectively cleaved by exploiting the sequence specificity of restriction endonucleases.  
We integrated unique restriction sites to each DNA sequence employed for cell sorting, 
and found that the adhesion of different populations of antigen-specific T cells could, in 
fact, be independently controlled (Figure 3.8).  Jurkatα-MART-1 and Jurkatα-Tyr cells 
prestained with lipophilic dyes (red and green respectively) were sorted on an array 
printed with DNA sequences AEcoRI and BBamHI (Figure 3.8i).  These oligonucleotides 
were modified by incorporating 6 bp restriction sites specific for endonucleases EcoRI 
and BamHI respectively.  After T cell immobilization, the array was treated with BamHI 
which cleaved the BBamHI spots and selectively released the bound Jurkatα-Tyr cells 
(Figure 3.8ii).  Conversely, on a separate but identically cell sorted array, Jurkatα-MART-1 
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cells were released after treatment with EcoRI (Figure 3.8iii).  A second round of 
enzymatic treatment with the complementary endonuclease (EcoRI to state (ii) or BamHI 
to state (iii)) removed the remaining adherent cells (iv, v)).  Alternatively all captured 
cells (i) could be released non-selectively in a single step with the addition of DNase (vi).  
 
 
Figure 3.8 Programmed release of sorted T cells by endonuclease cleavage (A) DNA 
sequences containing EcoRI and BamHI restriction sites were used for T cell sorting.  (B) 
Fluorescent images of Jurkatα-MART-1 (red) and Jurkatα-Tyro (green) cells captured on p/MHC array 
(i) and after treatment with BamHI (ii) or EcoRI (iii).  Only cells localized to DNA spots 
containing the target restriction sequence were released.  A second round of enzymatic treatment 
released the remaining bound cells (iv, v).  Panel (vi) illustrates the array after treatment of state 
(i) with DNase. 
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3.3.5 NACS sorting of endogenous primary human T cells 
Detection of primary human T cells isolated from peripheral blood is generally 
more demanding than cultured cell lines because a single population of antigen-specific T 
cells is present within a large background of differing blood cells and of T cells 
expressing monoclonal and polyclonal TCRs of diverse specificities.  In addition, these T 
cells would be expressing endogenous levels of TCR.  We explored whether the same 
attributes of NACS that were found in the above examples would apply equally to 
endogenous primary human T cells.  Frozen leukapheresis samples from patient NRA13 
were CD8+ enriched and applied to a CMV and Epstein-barr virus (EBV BMLF1259-
267/HLA-A2.1) p/MHC array.  T cells were captured only within the EBV regions only 
(Figure 3.9A).  NRA13 CD8+ cells were verified by flow cytometry to be ~5% EBV-
specific and ~0% CMV-specific (Figure 3.10A).  The registry of the array was 
determined with the addition of A’-cy3 (red) and B’-cy5 (blue) conjugates. 
For multiplexed detection, a 1:1 mixture of EBV-specific and CMV-specific 
CD8+ T cells was produced by combining NRA13 lymphocytes with CMV-specific T 
cells from patient NRA11 (Figure 3.10B).  Following cell sorting and fluorescent 
p/MHC tetramer staining, the populations were complementary stained for the 
appropriate antigen-specificity (Figure 3.9B).  The detection limit of antigen-specific T 
cells was evaluated from using serially diluted mixtures of EBV-specific T cells (~0.4%, 
0.2%, and 0.1% by FACS) that were probed on an array.  Isolated hits were resolved in 
frequencies as low as ~0.1% (Figure 3.11, red arrows).  The number of unstained cells 
within the capture regions (black arrow) was constant throughout all dilutions (~1–2 
cells/spot) and likely represents the level of background from non-specific interactions.  
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It should be noted that while we incorporated fluorescent p/MHC tetramer staining after 
T cell immobilization for illustrative purposes, the specificity of the captured cells could 
be determined solely from the registry of the array. 
 
Figure 3.9 NACS sorting of endogenous primary human T cells specific for Epstein-Barr 
virus and Cytomegalovirus (A) CD8+ T cells from patient NRA 13 were captured on EBV 
p/MHC spots and no T cells were captured on CMV spots (left panel).  The right two panels are 
representative images after the cells were stained with fluorescent EBV (blue) and CMV p/MHC 
tetramers (red). (B) T cells detected from a 1:1 mixture of NRA11 and NRA 13 (left panel) were 
verified to be specific for EBV and CMV (right panels).  
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Figure 3.10 The T cell specificities of PBMCs from patients NRA11 and NRA13 (A) 
Lymphocytes isolated from NRA13 contained significant levels of EBV specific T cells (4.9%) 
with minimal CMV specific T cells. (B) Lymphocytes isolated from NRA11 contained high 
levels of CMV specific T cells (9%) with a low population of EBV-specific cells (0.12%).  
Leukaphersis fractions from both patients were kept as frozen aliquots before thawing, CD8+ 
enrichment and NACS sorting. 
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Figure 3.11  Limit of detection of endogeneous human T cells with NACS Mixtures of ~0.4%, 
0.2% and 0.1% EBV-specific T cell populations (upper panels) were detected via NACS (bottom 
panels).   Populations of EBV-specific T cells are marked with red arrows and non-specific cells 
are marked with black arrows. 
 
3.3.6 Persistence of MART-1 specific, TCR-engineered human T cells in vivo 
One important potential application of NACS is to utilize the technique for 
monitoring cancer patients that are undergoing a particular type of immunotherapy that 
involves TCR engineering of peripheral blood mononuclear cells (PBMCs).  This is an 
emerging clinical approach to rapidly generate large numbers of tumor antigen-specific T 
cells.  In particular, a cancer patient’s T cells are collected, genetically modified to 
express a TCR specific for a desired cancer antigen, and then they are introduced back 
into the patient as a cancer therapy.  After re-infusion into the patient, the modified T 
cells can subsequently traffic to and engage with cancer cells, promoting tumor 
regression in a subset of patients with metastatic cancers.  This type of directed cell 
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therapy is utilized primarily in patients with melanoma (skin cancer), but also for other 
cancers (38, 39).  This approach is called adoptive cell transfer (ACT).  We monitored the 
presence and abundance of TCR-engineered T cells in peripheral blood of a patient 
undergoing ACT.  White blood cells were collected from patient F5-1 with metastatic 
melanoma.  After in vitro expansion and TCR transduction, the cells were > 80% specific 
for the MART-1 p/MHC tetramer (Figure 12A).  These cells were subsequently infused 
into patient F5-1 and the presence and persistence of MART-1-specific T cells in the 
peripheral blood was monitored by NACS at days 0 (prior to infusion), 9, 14 and 30 
(Figure 12B).  MART-1-specific T cells were not detectable in pre-infusion samples 
from the patient but they were detectable at all subsequent time points.  This is 
represented as a gradual rise in the abundance of MART-1-specific T cells until day 30 
(left axis).  In comparison, the frequency of MART-1-specific T cells detected by flow 
cytometry spiked initially before decreasing and finally increasing by day 30 (right axis).  
The abundance of TCR-engineered T cells, as measured by NACS, was generally 
correlated with parallel measurements using flow cytometry.  The prospect of array-based 
T cell detection schemes for experimental cancer immuno-therapies such as ACT will 
likely increase as more cancer associated antigens are identified and targeted.  For 
example, more than 50 different melanoma associated antigens have thus far been 
characterized (40, 41), and this means that more T cells types are likely to be employed 
for future therapies (39, 42, 43).  However, the desire to probe larger sets of cancer 
associated antigens will be compounded by the amount of sample that can be practically 
collected from a patient.  NACS appears to provide a feasible approach towards carrying 
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out the highly multiplexed cellular measurements that will eventually be required as 
ACT-like therapies move forward.    
 
Figure 3.12 Monitoring the presence of infused MART-1-specific, TCR-engineered T cells 
(A) Flow cytometry plots (top panels) and NACS (bottom panels) monitoring the transduction of 
T cells with a MART-1-specific TCR. (B) Blood cells from patient F5-1 were collected at days 0, 
9, 14 and 30 after infusion.  The abundance of MART-1-specific T cells was monitored by NACS 
(left axis) and flow cytometry (right axis). 
 
3.3.7 Homogeneous platform for cell sorting and functional analysis 
Antigen-specific T cells that are sorted by NACS are immobilized to a solid 
surface and are immediately available for further studies.  Traditional surface bound 
assays such as IHC, FISH and ELISPOT should integrate seamlessly with NACS.  In 
addition, antigen-specific T cells have been shown to be activated upon binding to 
p/MHC arrays (6–8) and secrete various immunomodulatory cytokines.  The cytokine 
secretion profiles of CD8+ T cells provide valuable information concerning the 
phenotype of the T cell (e.g. effector and anergic phenotypes can be differentiated by the 
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production of IFN-γ).  Thus integrating on-chip cytokine measurements with antigen-
specific T cell capture would greatly expand the diagnostic capability of NACS p/MHC 
tetramer arrays.   
 
Figure 3.13 Functional profiling of TCR triggered activation of captured antigen-specific T 
cells NACS ssDNA-p/MHC tetramers and DEAL anti-cytokine conjugates are both encoded to 
the same DNA sequence, co-hybridizing to the same spot.  CD8+ lymphocytes are activated upon 
binding to the p/MHC molecules, secreting cytokines which can be captured locally by DEAL 
conjugates.  After a predetermined period of incubation, a sandwich detection antibody is used to 
visualize the secreted product. 
We proceeded by integrating an ELISPOT-type sandwich assay with p/MHC 
NACS to detect cytokines produced by captured murine TCR transgenic splenocytes “on-
the-spot” (Figure 3.13).  Three murine anti-cytokine antibodies (IL-2, IFN-γ and TNF-α) 
were encoded with DNA strands A’, B’, and C’ respectively.  H-2Kb-OVA257-264 ssDNA-
p/MHC tetramers were encoded to all three strands.  The ssDNA-p/MHC tetramers and 
antibody conjugates were pooled and assembled to a microarray printed with the 
complementary strands A, B and C.  Murine OT1 lymphocytes (derived from TCR 
transgenic mice in which most splenocytes are specific for the model antigen OVA257-
264), were then seeded on the array.  Following incubation periods of 2, 5, or 18 hours, 
pooled cytokine detection antibodies were added and the slide imaged by confocal 
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microscopy (Figure 3.14A).  The inflammatory cytokine IFN-γ was detected at time 
points 5 and 18, manifest as discrete diffusive clusters (~50–100 μm in diameter at 5 hrs) 
that increased in average diameter temporally, attributable to molecular diffusion and 
sustained secretion.  Examination of the vicinity of each burst showed that underlying 
each fluorescent cluster was a single cell while neighboring cells appeared to be non-
responders (Figure 3.14B), suggestive that each IFN-γ burst was derived from a single 
cell.  The number of IFN-γ clusters remained constant at ~3 between hours 5 and 18, 
indicating no increase in the number of activated T cells between those hours.  No 
significant levels of murine IL-2 and TNF-α were detected at these time points. 
      
Figure 3.14 Dynamic cytokine profiling of NACS sorted murine OT1 lymphocytes (A) 
Discrete IFN-γ clusters were detected at 5 and 18 hours with no detectable presence of IL-2 and 
TNF-α.  No increase in the average number of IFN-γ clusters between time points 5 and 18 hours 
was observed. (B) Representative confocal and brightfield images of an IFN-γ burst.  Isolated T 
cells were detected (arrow) within the diffusive IFN-γ regions surrounded by non-responsive T 
cells.   
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3.4 Conclusions  
We have described a method for generating robust and modular p/MHC arrays for 
high efficiency T cell sorting.  The inclusion of a larger set of orthogonal DNA sequences 
(20, 25) will enable the modular assembly of higher order p/MHC arrays for T cell 
screening experiments (e.g. one working set of DNA sequences can be used 
interchangeably to generate any combination of p/MHC arrays).  This would find 
immediate utility in the field of TCR peptide epitope discovery where recently, novel 
antigen peptides were discovered via high-throughput CD8+ screening experiments 
utilizing multi-color flow cytometry in mice and humans (44, 45) (as many as 2,000 
distinct p/MHC tetramers were prepared and tested).  NACS arrays have the potential to 
streamline such experiments.  Although traditional methods of producing single p/MHC 
monomers are time and labor intensive, recent reports using conditional peptide exchange 
technology enables the relatively straightforward construction of 1000 element p/MHC 
libraries rapidly (44–46).  The integration of NACS with these peptide exchange 
technologies is a realistic option. 
We have also demonstrated a number of advantages of the NACS platform.  It 
significantly outperforms literature approaches that utilize surface-bound p/MHC 
tetramers to capture cells.  It is simple and inexpensive to implement since cell sorting is 
performed on glass substrates prepared via traditional DNA printing technologies. In 
addition, sorted cells may be selectively released, which should permit for the 
deployment of a host of bioanalytical methods on NACS sorted cells.  We envision that 
NACS will find uses beyond multiplexed sorting of T cells based on TCR specificity.  
The principal components of this platform—streptavidin-cysteine core and orthogonal 
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single stranded DNA sequences—were rationally developed to enable oriented coupling 
and spatial addressing.  Thus this platform is amenable to any family of binding proteins 
or small molecule binders labeled with biotin.  The increase in avidity of p/MHC 
tetramers over monomers as a consequence of the valency of SA should likewise extend 
to other capture agents, making it feasible to generate cellular arrays with probes ranging 
from high to moderate affinities like antibodies, aptamers or peptides. 
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3.6 Appendix A:  Protein Sequences 
Core streptavidin + Cys in pET-3a vector (NdeI/BamHI)  
 
     NdeI 
   1 CATATGGGCA TCACCGGCAC CTGGTACAAC CAGCTCGGCT CGACCTTCAT 
     H  M  G  I   T  G  T   W  Y  N   Q  L  G  S   T  F  I     
       
  51 CGTGACCGCG GGCGCCGACG GCGCCCTGAC CGGAACCTAC GAGTCGGCCG 
      V  T  A   G  A  D  G   A  L  T   G  T  Y   E  S  A  V    
 
 101 TCGGCAACGC CGAGAGCCGC TACGTCCTGA CCGGTCGTTA CGACAGCGCC 
       G  N  A   E  S  R   Y  V  L  T   G  R  Y   D  S  A           
 
 151 CCGGCCACCG ACGGCAGCGG CACCGCCCTC GGTTGGACGG TGGCCTGGAA 
     P  A  T  D   G  S  G   T  A  L   G  W  T  V   A  W  K     
 
 201 GAATAACTAC CGCAACGCCC ACTCCGCGAC CACGTGGAGC GGCCAGTACG 
      N  N  Y   R  N  A  H   S  A  T   T  W  S   G  Q  Y  V    
 
 251 TCGGCGGCGC CGAGGCGAGG ATCAACACCC AGTGGCTGCT GACCTCCGGC 
       G  G  A   E  A  R   I  N  T  Q   W  L  L   T  S  G      
 
 301 ACCACCGAGG CCAACGCCTG GAAGTCCACG CTGGTCGGCC ACGACACCTT 
     T  T  E  A   N  A  W   K  S  T   L  V  G  H   D  T  F     
  
                                      BamHI  
351 CACCAAGGTG GGTGGTTCTG GTTGCCCGTAG GGATCC                     
      T  K  V   G  G  S  G   C  P  *    
 
Human β2m in pET-3a vector NdeI/BamHI 
     NdeI 
   1 CATATGATCC AGCGTACTCC AAAGATTCAG GTTTACTCAC GTCATCCAGC 
     H  M  I  Q   R  T  P   K  I  Q   V  Y  S  R   H  P  A     
 
  51 AGAGAATGGA AAGTCAAATT TCCTGAATTG CTATGTGTCT GGGTTTCATC 
      E  N  G   K  S  N  F   L  N  C   Y  V  S   G  F  H  P    
 
 101 CATCCGACAT TGAAGTTGAC TTACTGAAGA ATGGAGAGAG AATTGAAAAA 
       S  D  I   E  V  D   L  L  K  N   G  E  R   I  E  K      
 
 151 GTGGAGCATT CAGACTTGTC TTTCAGCAAG GACTGGTCTT TCTATCTCTT 
     V  E  H  S   D  L  S   F  S  K   D  W  S  F   Y  L  L     
 
 201 GTATTATACT GAATTCACCC CCACTGAAAA AGATGAGTAT GCCTGCCGTG 
      Y  Y  T   E  F  T  P   T  E  K   D  E  Y   A  C  R  V    
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 251 TGAACCACGT GACTTTGTCA CAGCCCAAGA TAGTTAAGTG GGATCGAGAC 
       N  H  V   T  L  S   Q  P  K  I   V  K  W   D  R  D      
 
            BamHI 
 301 ATGTAA GGATCC                                          
     M  *        
 
Human HLA-A2.1 (biotin tag) 
   1 ATGGGCTCTC ACTCCATGAG GTATTTCTTC ACATCCGTGT CCCGGCCCGG 
     M  G  S  H   S  M  R   Y  F  F   T  S  V  S   R  P  G     
 
  51 CCGCGGGGAG CCCCGCTTCA TCGCAGTGGG CTACGTGGAC GACACGCAGT 
      R  G  E   P  R  F  I   A  V  G   Y  V  D   D  T  Q  F   
 
 101 TCGTGCGGTT CGACAGCGAC GCCGCGAGCC AGAGGATGGA GCCGCGGGCG 
       V  R  F   D  S  D   A  A  S  Q   R  M  E   P  R  A      
 
 151 CCGTGGATAG AGCAGGAGGG TCCGGAGTAT TGGGACGGGG AGACACGGAA 
     P  W  I  E   Q  E  G   P  E  Y   W  D  G  E   T  R  K     
 
 201 AGTGAAGGCC CACTCACAGA CTCACCGAGT GGACCTGGGG ACCCTGCGCG 
      V  K  A   H  S  Q  T   H  R  V   D  L  G   T  L  R  G    
 
 251 GCTACTACAA CCAGAGCGAG GCCGGTTCTC ACACCGTCCA GAGGATGTAT 
       Y  Y  N   Q  S  E   A  G  S  H   T  V  Q   R  M  Y      
 
 301 GGCTGCGACG TGGGGTCGGA CTGGCGCTTC CTCCGCGGGT ACCACCAGTA 
     G  C  D  V   G  S  D   W  R  F   L  R  G  Y   H  Q  Y     
 
 351 CGCCTACGAC GGCAAGGATT ACATCGCCCT GAAAGAGGAC CTGCGCTCTT 
      A  Y  D   G  K  D  Y   I  A  L   K  E  D   L  R  S  W    
 
 401 GGACCGCGGC GGACATGGCA GCTCAGACCA CCAAGCACAA GTGGGAGGCG 
       T  A  A   D  M  A   A  Q  T  T   K  H  K   W  E  A      
 
 451 GCCCATGTGG CGGAGCAGTT GAGAGCCTAC CTGGAGGGCA CGTGCGTGGA 
     A  H  V  A   E  Q  L   R  A  Y   L  E  G  T   C  V  E     
 
 501 GTGGCTCCGC AGATACCTGG AGAACGGGAA GGAGACGCTG CAGCGCACGG 
      W  L  R   R  Y  L  E   N  G  K   E  T  L   Q  R  T  D    
                
 551 ACGCCCCCAA AACGCATATG ACTCACCACG CTGTCTCTGA CCATGAAGCC 
       A  P  K   T  H  M   T  H  H  A   V  S  D   H  E  A      
 
 601 ACCCTGAGGT GCTGGGCCCT GAGCTTCTAC CCTGCGGAGA TCACACTGAC 
     T  L  R  C   W  A  L   S  F  Y   P  A  E  I   T  L  T     
 
 651 CTGGCAGCGG GATGGGGAGG ACCAGACCCA GGACACGGAG CTCGTGGAGA 
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      W  Q  R   D  G  E  D   Q  T  Q   D  T  E   L  V  E  T    
 
 701 CCAGGCCTGC AGGGGATGGA ACCTTCCAGA AGTGGGCGGC TGTGGTGGTG 
       R  P  A   G  D  G   T  F  Q  K   W  A  A   V  V  V      
 
 751 CCTTCTGGAC AGGAGCAGAG ATACACCTGC CATGTGCAGC ATGAGGGTTT 
     P  S  G  Q   E  Q  R   Y  T  C   H  V  Q  H   E  G  L     
 
 801 GCCCAAGCCC CTCACCGGAT CCGGTGGTTC CGGTGGTTCC GCGGGTGGTG 
      P  K  P   L  T  G  S   G  G  S   G  G  S   A  G  G  G    
 
 851 GTTTGAACGA CATCTTCGAA GCTCAGAAAA TCGAATGGCA CTAA       
       L  N  D   I  F  E   A  Q  K  I   E  W  H   *      
BirA ligase biotin sequence: GGGLNDIFEAQKIEWH 
 
Murine β2m  
   1 ATGATCCAGA AAACCCCTCA AATTCAAGTA TACTCACGCC ACCCACCGGA 
     M  I  Q  K   T  P  Q   I  Q  V   Y  S  R  H   P  P  E     
 
  51 GAATGGGAAG CCGAACATAC TGAACTGCTA CGTAACACAG TTCCACCCGC 
      N  G  K   P  N  I  L   N  C  Y   V  T  Q   F  H  P  P    
 
 101 CTCACATTGA AATCCAAATG CTGAAGAACG GGAAAAAAAT TCCTAAAGTA 
       H  I  E   I  Q  M   L  K  N  G   K  K  I   P  K  V      
 
 151 GAGATGTCAG ATATGTCCTT CAGCAAGGAC TGGTCTTTCT ATATCCTGGC 
     E  M  S  D   M  S  F   S  K  D   W  S  F  Y   I  L  A     
 
 201 TCACACTGAA TTCACCCCCA CTGAGACTGA TACATACGCC TGCAGAGTTA 
      H  T  E   F  T  P  T   E  T  D   T  Y  A   C  R  V  K    
 
 251 AGCATGACAG TATGGCCGAG CCCAAGACCG TCTACTGGGA TCGAGACATG 
       H  D  S   M  A  E   P  K  T  V   Y  W  D   R  D  M      
 
 301 TGA                                                    
     *   
 
Murine Κb (biotin tag) 
      NdeI 
   1 CATATGGGTC CACACTCTCT GCGCTATTTC GTTACGGCTG TTAGCCGTCC 
     H  M  G  P   H  S  L   R  Y  F   V  T  A  V   S  R  P     
 
  51 GGGTCTGGGT GAGCCGCGCT ACATGGAAGT CGGTTACGTC GACGACACCG 
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      G  L  G   E  P  R  Y   M  E  V   G  Y  V   D  D  T  E    
 
 101 AATTCGTGCG TTTCGACAGC GACGCGGAGA ACCCGCGTTA TGAGCCGCGT 
       F  V  R   F  D  S   D  A  E  N   P  R  Y   E  P  R      
 
 151 GCGCGTTGGA TGGAGCAGGA AGGTCCGGAG TACTGGGAGC GTGAAACGCA 
     A  R  W  M   E  Q  E   G  P  E   Y  W  E  R   E  T  Q     
 
 201 AAAGGCGAAG GGCAATGAAC AGAGCTTTCG TGTTGATCTG CGCACTCTGC 
      K  A  K   G  N  E  Q   S  F  R   V  D  L   R  T  L  L    
 
 251 TGGGTTACTA CAACCAGAGC AAAGGTGGCA GCCATACCAT TCAGGTGATT 
       G  Y  Y   N  Q  S   K  G  G  S   H  T  I   Q  V  I      
 
 301 AGCGGTTGTG AAGTCGGCTC TGATGGCCGC CTGTTGCGCG GTTATCAGCA 
     S  G  C  E   V  G  S   D  G  R   L  L  R  G   Y  Q  Q     
 
 351 ATATGCATAC GACGGTTGCG ACTACATTGC GCTGAATGAA GATCTGAAAA 
      Y  A  Y   D  G  C  D   Y  I  A   L  N  E   D  L  K  T    
 
 401 CGTGGACTGC GGCGGACATG GCCGCACTGA TTACCAAACA CAAGTGGGAG 
       W  T  A   A  D  M   A  A  L  I   T  K  H   K  W  E      
 
 451 CAAGCGGGCG AAGCCGAGCG CCTGCGTGCG TATCTGGAAG GCACCTGTGT 
     Q  A  G  E   A  E  R   L  R  A   Y  L  E  G   T  C  V     
 
 501 GGAATGGCTG CGCCGCTATC TGAAGAATGG CAATGCCACG TTGCTGCGTA 
      E  W  L   R  R  Y  L   K  N  G   N  A  T   L  L  R  T    
 
 551 CGGATTCCCC GAAAGCGCAC GTGACGCACC ATAGCCGTCC TGAGGATAAA 
       D  S  P   K  A  H   V  T  H  H   S  R  P   E  D  K      
 
 601 GTTACCCTGC GTTGCTGGGC ACTGGGCTTT TACCCGGCAG ATATCACCTT 
     V  T  L  R   C  W  A   L  G  F   Y  P  A  D   I  T  L     
 
 651 GACGTGGCAA CTGAATGGTG AAGAGCTGAT TCAGGATATG GAACTGGTGG 
      T  W  Q   L  N  G  E   E  L  I   Q  D  M   E  L  V  E    
 
 701 AGACTCGTCC GGCTGGCGAC GGTACCTTCC AGAAATGGGC ATCGGTTGTC 
       T  R  P   A  G  D   G  T  F  Q   K  W  A   S  V  V      
 
 751 GTCCCTCTGG GTAAAGAGCA ATACTATACC TGCCACGTTT ACCACCAAGG 
     V  P  L  G   K  E  Q   Y  Y  T   C  H  V  Y   H  Q  G     
 
 801 TCTGCCGGAG CCGCTGACCT TGCGTTGGGA GCCACCGCCG AGCACCGGCA 
      L  P  E   P  L  T  L   R  W  E   P  P  P   S  T  G  S    
 
 851 GCGGTGGTAG CGGCGGTTCC GCGGGTGGCG GTCTGAACGA CATCTTTGAG 
       G  G  S   G  G  S   A  G  G  G   L  N  D   I  F  E      
 
                               BamHI 
 901 GCCCAGAAGA TCGAGTGGCA TTAAGGATCC                       
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     A  Q  K  I   E  W  H   *      
 
BirA ligase biotin sequence: GGGLNDIFEAQKIEWH 
 
Murine Db (biotin tag) 
   1 ATGGGCCCAC ACTCGATGCG GTATTTCGAG ACCGCCGTGT CCCGGCCCGG 
     M  G  P  H   S  M  R   Y  F  E   T  A  V  S   R  P  G     
 
  51 CCTCGAGGAG CCCCGGTACA TCTCTGTCGG CTATGTGGAC AACAAGGAGT 
      L  E  E   P  R  Y  I   S  V  G   Y  V  D   N  K  E  F    
 
 101 TCGTGCGCTT CGACAGCGAC GCGGAGAATC CGAGATATGA GCCGCGGGCG 
       V  R  F   D  S  D   A  E  N  P   R  Y  E   P  R  A      
 
 151 CCGTGGATGG AGCAGGAGGG GCCGGAGTAT TGGGAGCGGG AAACACAGAA 
     P  W  M  E   Q  E  G   P  E  Y   W  E  R  E   T  Q  K     
 
 201 AGCCAAGGGC CAAGAGCAGT GGTTCCGAGT GAGCCTGAGG AACCTGCTCG 
      A  K  G   Q  E  Q  W   F  R  V   S  L  R   N  L  L  G    
 
 251 GCTACTACAA CCAGAGCGCG GGCGGCTCTC ACACACTCCA GCAGATGTCT 
       Y  Y  N   Q  S  A   G  G  S  H   T  L  Q   Q  M  S      
 
 301 GGCTGTGACT TGGGGTCGGA CTGGCGCCTC CTCCGCGGGT ACCTGCAGTT 
     G  C  D  L   G  S  D   W  R  L   L  R  G  Y   L  Q  F     
 
 351 CGCCTATGAA GGCCGCGATT ACATCGCCCT GAACGAAGAC CTGAAAACGT 
      A  Y  E   G  R  D  Y   I  A  L   N  E  D   L  K  T  W    
 
 401 GGACGGCGGC GGACATGGCG GCGCAGATCA CCCGACGCAA GTGGGAGCAG 
       T  A  A   D  M  A   A  Q  I  T   R  R  K   W  E  Q      
 
 451 AGTGGTGCTG CAGAGCATTA CAAGGCCTAC CTGGAGGGCG AGTGCGTGGA 
     S  G  A  A   E  H  Y   K  A  Y   L  E  G  E   C  V  E     
 
 501 GTGGCTCCAC AGATACCTGA AGAACGGGAA CGCGACGCTG CTGCGCACAG 
      W  L  H   R  Y  L  K   N  G  N   A  T  L   L  R  T  D    
 
 551 ATTCCCCAAA GGCACATGTG ACCCATCACC CCAGATCTAA AGGTGAAGTC 
       S  P  K   A  H  V   T  H  H  P   R  S  K   G  E  V      
 
 601 ACCCTGAGGT GCTGGGCCCT GGGCTTCTAC CCTGCTGACA TCACCCTGAC 
     T  L  R  C   W  A  L   G  F  Y   P  A  D  I   T  L  T     
 
 
 651 CTGGCAGTTG AATGGGGAGG AGCTGACCCA GGACATGGAG CTTGTGGAGA 
      W  Q  L   N  G  E  E   L  T  Q   D  M  E   L  V  E  T    
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 701 CCAGGCCTGC AGGGGATGGA ACCTTCCAGA AGTGGGCATC TGTGGTGGTG 
       R  P  A   G  D  G   T  F  Q  K   W  A  S   V  V  V      
 
 751 CCTCTTGGGA AGGAGCAGAA TTACACATGC CGTGTGTACC ATGAGGGGCT 
     P  L  G  K   E  Q  N   Y  T  C   R  V  Y  H   E  G  L     
 
 801 GCCTGAGCCC CTCACCCTGA GATGGGAGCC TCCTCCATCC ACTGGATCCG 
      P  E  P   L  T  L  R   W  E  P   P  P  S   T  G  S  G    
 
 851 GTGGTTCCGG TGGTTCCGCG GGTGGTGGTT TGAACGACAT CTTCGAAGCT 
       G  S  G   G  S  A   G  G  G  L   N  D  I   F  E  A      
 
 901 CAGAAAATCG AATGGCACTA A                                
     Q  K  I  E   W  H  *   
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3.7 Appendix B:  Chromatography 
 
3.7.1 Iminobiotin Purification of SAC 
 
Figure 3.15  SAC purification with an iminobiotin agarose support column.  (A) The 
structure of biotin.  (B) Iminobiotin, the structural analog of biotin, has two distinct states; (1) a 
neutral, high affinity SAC binding state at pH 11 and a cationic state, low affinity SAC binding 
state at pH 4.  (C) Elution profile of SA compared to SAC refolded in various buffers.   
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3.7.2 FPLC of SAC-ssDNA conjugates 
 
*0.5ml/min isocratic flow of PBS 
Figure 3.16  Fast protein liquid chromatography of ssDNA-SAC conjugates.  A typical 
successful conjugation reaction will yield three distinct peaks, corresponding to the ssDNA-SAC 
conjugates, excess unreacted ssDNA, and excess small molecules.  It is possible to resolve 
shoulders in the ssDNA-SAC peak, corresponding to extent of ssDNA modification. 
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Chapter 4 
Detection of Cell Surface Markers with Encoded 
ssDNA Reporters: Towards Global Cell Surface-
ome Profiling    
 
 
 
 
4.1   Introduction 
The proteins on the surface of the cell membrane play important roles in various 
aspects of tumor biology.  Cell surface markers are involved in cancer pathogenesis, aid 
in staging, and represent a large class of proteins targeted for therapy.  The importance of 
the membrane-bound oncogenes EGFR and ERBB2 and the development of small 
molecule inhibitors against them have been expounded on in the previous chapters.  
Identification of altered or expression of cancer associated surface antigens is an area of 
active research.  For example, the cell surface marker CD40 has been found to be 
expressed in many B cell malignancies and has been investigated as the possible target 
for anti-CD40 antibody-based cancer therapy (1).  Development of methods that enable 
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comprehensive mapping of the cell surface proteome would provide new avenues for 
investigation, analogous to the effect global transcriptome expression profiling has had in 
providing valuable fundamental and therapeutic information for various types of cancers 
(2).  However, there have been few documented effective strategies for high-throughput, 
global profiling of surface membrane proteins.  One approach is to purify cellular 
membrane fragments by two-phase separation, but cross-contamination from cytosolic 
proteins is a major limitation (3).  Other reports have demonstrated the feasibility of 
retrieving membrane fragments in vivo from endothelial cells using a combination of 
colloidal silica particles and polymers (4).  Membrane proteins have also been isolated 
through chemical biotinylation followed by enrichment with a streptavidin column (5–7).  
Typically after enrichment, the membrane bound proteins are identified by the 
combination of 2-D gel electrophoresis and mass spectrometry.  A major limitation of 
these studies is that the labeling strategies are non-specific and the biological samples are 
lysed, precluding dynamic studies.   
In this chapter summarizing current work, I present an antibody-based, 
membrane-protein profiling approach, which uses a library of capture agents to probe 
membrane-bound antigens.  Similar to DEAL or NACS conjugates, each capture agent is 
conjugated to a distinct ssDNA tag but differs in that the sequence incorporates a photo-
labile base.  The capture agents are allowed to bind to cell surface antigens, after which 
the ssDNA tags are released into solution by UV-induced cleavage, collected and 
detected by PCR (Figure 4.1).  This approach is called cellular barcoding.  There have 
been quite a few studies integrating the specificity of antibodies for antigen detection 
with nucleic acid readouts, including immuno-PCR (8–10), immunodetection amplified 
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by T7 RNA polymerase (11–12), proximity ligation (13–14), and nanoparticle assays 
(15).  However, all these assays were used to detect single proteins in idealized solutions, 
and were not utilized in a high throughput, multi-parameter manner for detecting and 
profiling cell surface proteins.   
 
Figure 4.1 Schematic of cellular barcoding A collection of capture agents conjugated 
with distinct ssDNA tags is applied to a biological cell sample.  After binding to the 
cognate membrane-bound protein, the ssDNA tags are photocleaved and collected for 
analysis by PCR.  The frequency of the ssDNA barcodes correlate to the expression level 
of cell membrane proteins.    
 
4.2 Experimental Methods 
4.2.1 DNA sequences and production of conjugates 
 All DNA sequences were purchased with HPLC purification from Integrated 
DNA Technologies (www.idtdna.com) and are listed in Table 4.1.  
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Table 4.1  Cellular barcoding DNA sequences  
 
Name    Sequence*
 
PC1  
 5’ – NH2 – PC – ATC CTG GAG CTA AGT CCG TAG CCT CAT TGA ATC ATG CCT 
AGC ACT CGT CTA CTA TCG CTA 
PC forward primer 
 5’ – ATG GTC GAG ATG TCA GAG TAA TCC TGG AGC TAA GTC CGT A 
PC reverse primer 
 5’ – TAG ATA CTG CCA CTT CAC ATT AGC GAT AGT AGA CGA GTG C 
A’          5' - NH2- AAA AAA AAA ATA CGG ACT TAG CTC CAG GAT-cy3 
*  The 5’ amine functional group for sequences PC and EcoRV is necessary to conjugate 
the oligonucleotide to SAC or antibodies.     
1 PC = photocleavable 
Antibody-ssDNA (DEAL) conjugates were synthesized, purified and characterized 
according to previously published protocols (16).  The HLA-A*0201 restricted MHC class I 
monomers loaded with MART-126-35 (ELAGIGILTV) were produced in house according 
to previous published protocols (17).  The production of p/MHC-ssDNA constructs 
(NACS conjugates) were according to previous published protocols (18). 
4.2.2 Detection of surface markers with PCR 
 Prior to all experiments, blocking buffer (1.5% BSA, 150 μg/ml salmon sperm 
DNA in PBS) was used to block all 1.5 ml tubes and a 96-well plate for 1 hour at room 
temperature (RT) before rinsing 2x with PBS.  The blocked tubes and plate were used 
immediate for experiments.  One million cells (Jurkatα-MART-1, Jurkatα-Tyro, or GBM1600) 
were transferred to 1.5 ml tubes, and resuspended in 100 μl staining buffer (HBSS 
supplemented with 2.5mg/ml BSA, 10mM HEPES, 0.01% azide).  The cells were 
blocked by adding 100 μl of 2mg/ml salmon sperm DNA for 20 min. at 37oC before 
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resuspension in staining buffer.  Capture agents tagged with ssDNA (Cetuximab, MART-
1) were added (0.5 μg per 106 cells) to the cell suspension for 20–25 min. at 37oC.  The 
samples were then washed 3x with staining buffer before a final wash and resuspension 
in 1% BSA PBS.  For UV-dependent cleavage of the ssDNA tags, 5 x 105 cells in 50 μl 
were transferred to a 96-well plate on ice and exposed to long wave UV for 1 hr.  The 
cells were pelleted and the supernatant containing the DNA codes was collected for PCR 
analysis.   
4.3 Results and Discussion 
4.3.1 Detection of differential cell surface expression of EGFR 
 To illustrate the feasibility of using ssDNA-antibody conjugates to detect 
membrane-bound proteins by PCR, we selected two cell lines expressing differing levels 
of human epidermal growth factor receptor (EGFR).  GBM1600 cells are a low-passage 
cell line derived from a primary brain tumor expressing high levels of EGFR.  Jurkat cells 
are a hematopoietic derived T cell line with null expression of EGFR.  The presence or 
absence of EGFR expression was verified flow cytometry (Figure 4.2A).     
We prepared anti-EGFR (Cetuximab) conjugated with photocleavable ssDNA 
oligonucleotide (PC) and stained GBM1600 and Jurkat cells in separate tubes with the 
conjugate.  After removing excess Cetuximab-PC molecules, the samples were treated in 
a 96-well plate with UV radiation for one hour.  The photo-cleaved ssDNA tags were 
collected, amplified by PCR and visualized on a 4% agarose gel.  As shown in Figure 
4.3, the reporter tags were detected at an earlier thermal cycle during the amplification in 
the GBM1600 sample than in the Jurkat sample.  Quantitative assessment by Q-PCR 
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gave a ΔCt of approximately ~8.6 (Figure 4.3b).  Under ideal experimental conditions, 
each thermal cycle doubles the total number of amplicons.  Assuming EGFR expression 
directly correlates with the number of ssDNA tags released in solution, the relative 
difference in EGFR expression between the GBM1600 and Jurkat samples is given by 
28.6, which is approximately equal to 400.  In reality, since most processes are non-ideal, 
this likely represents the upper bound.  Assuming each thermal cycle increases the 
number of amplicons by a factor of 1.8 instead of 2 gives a relative difference of 1.88.6, 
which is approximately equal to 160.   
 
 
Figure 4.2 Antibody-ssDNA and p/MHC-ssDNA tetramers stain cells in solution (A)  Flow 
cytometry analysis of EGFR expression of GBM1600 (blue) and Jurkat (green) cells.  GBM1600 
EGFR expression was significantly higher than the Jurkat control cell line. (B) Flow cytometry 
analysis of TCR expression.  Jurkatα-MART-1 cells were stained by MART-1-A’ and MART-1-APC 
p/MHC tetramers (right panels).  Jurkatα-Tyr cells were not stained by MART-1-A’ tetramers 
(lower left panel).   
     
112 
 
 
Figure 4.3 GBM1600 EGFR detection by cellular barcoding (A) Acrylamide gel 
electrophoresis of amplified products collected every 5th complete thermal cycle.  Reporter 
ssDNA tags were detected earlier in GBM1600 samples than in Jurkat samples. (B) Ct values by 
Q-PCR. 
 
4.3.2 Cellular barcoding limits of detection 
 In order to determine the minimum number of cells required for surface antigen 
detection, two avenues were investigated.  First, GBM1600 cells were spiked into Jurkat 
cells to produce synthetic cellular mixtures composed of 100%, 10%, 1%, 0.1%, or 0% 
GBM1600 cells.  The total number of cells per condition was kept constant at 106 by 
increasing the number of Jurkat cells.  Second, GBM1600 cells were serially diluted into 
separate tubes, each containing either 105, 104, 103, 102, or 0 cells per tube.  No Jurkat 
cells were added to these vials.  These samples were stained using Cetuximab-PC 
conjugates and the results are shown in Figure 4.5.  For the cell mixtures, GBM1600 
cells at 100% and 10% were detected significantly above the baseline while mixtures 1% 
and 0.1% were similar in intensity to the baseline (Figure 4.5A).  In the serial dilutions, 
samples containing 104 cells or more were detected above background (Figure 4.5B).  
Significant signal arose from the vial without any cells, which is likely due to non-
specific interactions between Cetuximab-PC conjugates and the vial.  We are currently 
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investigating improvements in the blocking and washing steps to increase the signal to 
noise ratio.          
 
Figure 4.4 Limits of detection (A) Synthetic samples of spiked GBM1600 cells in Jurkat 
cells were detected by α-Cetuximab-ssDNA conjugate, with a dilution limit of about 10% 
(B) Reporter ssDNA amplification can detect EGFR expression from >  104 cells.   
 
4.3.2 Detection of antigen-specific T cells using ssDNA-p/MHC tetramers 
 The ability to profile T cell receptors has many potential fundamental applications 
in immunology as well as diagnostic potential in many fields like vaccine development, 
immune monitoring, and cancer immunotherapy.  Since the development of p/MHC 
tetramers (19), it has been possible to directly analyze populations of antigen-specific T 
cells by staining with fluorescent p/MHC tetramers.  The fundamental limitation in this 
approach is the difficulty in multiplexing since distinct T cell specificities need to be 
encoded with different colors for discrimination.  Therefore, there has been widespread 
interest in developing p/MHC protein arrays, since in a spatially encoded format, the 
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degree of multiplexing can be increased greatly (18, 20-23).  One inherent limitation of 
array approaches however, is that the sensitivity and scalability is limited by the size of 
the spots, since the sensitivity is directly proportional to the diameter of the capture 
surfaces.  In addition, arrays approaches are planar substrate-based detection schemes.  
The limited diffusive capacity of T cells prevents cells from sampling an entire array.  
Hence for all arrays approaches, T cell recovery is low.  The majority of the cells settle 
on inert areas of the substrate or on non-cognate spots.  With an approach like cellular 
barcoding, the engagement of the encoding agent with the cell surface receptor occurs in 
solution.  Thus by using NACS conjugates, all T cells in a solution is encoded after 
staining and can subsequently be decoded.   
To demonstrate the feasibility of detecting antigen-specific TCRs with cellular 
barcoding, the T cell lines Jurkatα-MART-1 and Jurkatα-Tyr were chosen as the model lines.  
These are transduced T cells expressing TCRs specific for the antigens MART-1 and 
tyrosinase respectively and were described in detail in chapter 3.  MART-1 p/MHC 
tetramers were prepared encoded with fluorescent DNA (A’) or photocleavable DNA 
(PC).  MART-1-A’ p/MHC tetramers were compared with fluorescent MART-1-APC 
p/MHC tetramers for their ability to stain Jurkatα-MART-1 cells.  The results are shown in 
Figure 4.2B.  Both tetramers stained Jurkatα-MART-1  cells similarly (right upper, right 
lower panels).  Importantly, cells expressing the non-cognate TCR were not stained by 
MART-1-A’ tetramers (lower left panel), demonstrating that p/MHC tetramers appended 
with ssDNA pendants can engage with the cognate TCR in the suspension phase.         
Both T cell lines were then stained with MART-1-PC tetramers, treated with UV 
and analyzed by PCR.  The results are shown in Figure 4.4.  Approximately five fewer 
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thermal cycles were required before PC was detected from the Jurkatα-MART-1 sample than 
from the Jurkatα-Tyr sample.  In comparison with EGFR detection by Cetuximab-PC, the 
discrimination between the two T cell lines is less significant.  This may be attributed to 
higher affinity Cetuximab-PC conjugates relative to ssDNA-p/MHC complexes.  We are 
currently investigating more comprehensive purification strategies that would yield the 
highest avidity ssDNA-p/MHC complex by separating fully tetrameric p/MHC constructs 
from complexes of lower valency.     
       
Figure 4.5 Antigen-specific T cell detection by cellular barcoding  PCR analysis of 
ssDNA tags showing specific detection of Jurkata-MART-1 over control Jurkata-Tyr cells 
when interrogated with MART-1-ssDNA p/MHC tetramer.      
 
4.4 Conclusions and Future Directions 
 In its present state, the dynamic range of membrane antigen detection with 
antibody-DNA conjugates is approximately 102.  This is sufficient in distinguishing cells 
that express a surface antigen from cells that do not, since most proteins are found on the 
cell surface at approximately 2,000–500,000 copies per cell (24).  Improvements to this 
technique that expands the dynamic range will be beneficial as well as improvements that 
116 
 
lower the sensitivity of this approach, which would allow the detection of membrane 
proteins from small sample sizes below 104 cells.  In addition, with heterogeneous 
mixtures of cells, it may be necessary to enrich for a particular phenotype prior to cellular 
barcoding, since a surface antigen that has been detected cannot be assigned to any 
particular cell type within a mixture a priori.  To this end, it may be advantageous to 
integrate DEAL/NACS cell sorting prior to barcoding. 
 While this demonstration using conventional PCR highlights the technical 
feasibility of this approach, the goal is integration with high-throughput sequencing 
employing the Solexa platform.  This second generation sequencer works by ligating 
cDNA libraries to the bottom of microfluidic flow cells.  The flow cells are sufficiently 
large to ensure scattered coverage, enabling spatial resolution of individual cDNA 
fragments.  After in situ amplification, the sequences are read by a sequence-by-synthesis 
approach.  Typically, 25 base pair reads are taken from 107–108 possible unique 
sequences per flow cell (25, 26).  This approach is digital and quantitative because each 
read is from a cDNA fragment that is spatially resolved.  By integrating a library of 
capture agents encoded with ssDNA identifiers with Solexa sequencing, it should be 
possible to generate a quantitative cell surface-ome heat map.  A schematic is illustrated 
in Figure 4.6. 
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Figure 4.6 Schematic of global “surface-ome” profiling with cellular barcoding  
A pool of reporter ssDNA tags get can sequenced with second generational, high-
throughput sequencers (e.g. Solexa platform), enabling absolute quantification of 
membrane bound protein expression in cellular samples. 
 There are several DNA sequence design considerations to interface with Solexa 
sequencing.  First, since 25 base pair reads are commonly employed, the barcoding 
segment of the DNA should lie within 25 base pairs from the 5’ or 3’ end.  Second, the 
barcoding region can be small.  A stretch of 6 bases will encode for 46 = 4096 different 
parameters.  Third, prior to ligation to the flow cell, small cDNA libraries are typically 
amplified by PCR.  To avoid biasing the ssDNA tag library, universal primers can be 
integrated, flanking the barcode (Figure 4.7A).  Lastly, because of the high-throughput 
and current cost of each sequencing run, it should be possible to utilize different sets of 
universal primers with 3 base pair overhangs as experimental identifiers.  This would 
allow barcode tags from multiple experiments to be pooled together for a single 
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sequencing run (Figure 4.7B).  A 3 base stretch would allow 43 = 64 different 
experiments to be pooled together. 
 
Figure 4.7 DNA sequence design considerations (A) Illustration of a generic DNA sequence 
that can interface with Solexa sequencing containing two universal primers flanking a 6 bp 
encoding region.  Six bases encodes for 4096 different parameters. (B) Because the throughput of 
second generation sequencers are high, experimental ID tags can be integrated through unique set 
of universal primers, enabling multiple experiments to be decoded and sequenced simultaneously.  
A three base stretch is sufficient to encode 64 unique experiments.  
 In conclusion, a solution phase approach has been introduced that allow cell 
membrane bound proteins to be detected by capture agents like antibodies or p/MHC 
tetramers encoded with ssDNA tags.  The pendant oligonucleotides function as reporter 
molecules that can be detected and quantified with conventional thermal amplification 
approaches.  The successful integration of a library of ssDNA-encoded captured agents 
with high-throughput sequencing for quantitative assessment would provide a global 
profiling tool to survey the cell surface-ome with fundamental and diagnostic 
implications.   
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